ACR Meeting Abstracts

ACR Meeting Abstracts

Session » ACR Convergence 2021

Abstract Number: L09
A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children
Abstract Number: L15
A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach
Abstract Number: L10
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
Abstract Number: L08
Association of Limited Health Literacy with Clinical and Patient-Reported Outcomes in Systemic Lupus Erythematosus: An Analysis from the Peer Approaches to Lupus Self-Management (PALS) Program
Abstract Number: L11
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: L06
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Abstract Number: L03
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
Abstract Number: L02
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Abstract Number: L07
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Abstract Number: L14
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
Abstract Number: L13
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Abstract Number: L01
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Abstract Number: L12
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Abstract Number: L05
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Abstract Number: L04
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
8:30AM-10:30AM
Abstract Number: 0287
20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
8:30AM-10:30AM
Abstract Number: 0282
5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
8:30AM-10:30AM
Abstract Number: 0365
A Cluster Analysis in Patients with Axial Spondyloarthritis Using TNFi Based on Clinical Characteristics
8:30AM-10:30AM
Abstract Number: 0251
A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults
8:30AM-10:30AM
Abstract Number: 0354
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0168
A Crowdsourcing Approach to Develop Machine Learning Models to Quantify Radiographic Joint Damage in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0408
A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography
8:30AM-10:30AM
Abstract Number: 0325
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0031
A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
8:30AM-10:30AM
Abstract Number: 0012
A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen
8:30AM-10:30AM
Abstract Number: 0048
A Novel Technology to Study the Role of Intestinal Biology in Spondyloarthritis Pathogenesis: Human Colonic Organoids and Epithelial Monolayers
8:30AM-10:30AM
Abstract Number: 0147
A Qualitative Analysis of Methotrexate Self-Injection Education Videos on YouTube: An Update
8:30AM-10:30AM
Abstract Number: 0112
A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics
8:30AM-10:30AM
Abstract Number: 0047
A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0196
A Single Center, Double Blind, Randomized, Placebo-Controlled Trial of Anakinra in Adult Patients with Features of Cytokine Storm Syndrome in COVID-19
8:30AM-10:30AM
Abstract Number: 0384
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
8:30AM-10:30AM
Abstract Number: 0178
Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?
8:30AM-10:30AM
Abstract Number: 0273
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0107
Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
8:30AM-10:30AM
Abstract Number: 0362
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0301
Activation of Akt Signaling Pathway in the Minor Salivary Glands of Patients with Primary Sjögren’s Syndrome Does Not Relate with Clinical Phenotype
8:30AM-10:30AM
Abstract Number: 0341
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
8:30AM-10:30AM
Abstract Number: 0104
Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
8:30AM-10:30AM
Abstract Number: 0306
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0065
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
8:30AM-10:30AM
Abstract Number: 0205
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
8:30AM-10:30AM
Abstract Number: 0428
ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0274
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
8:30AM-10:30AM
Abstract Number: 0073
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
8:30AM-10:30AM
Abstract Number: 0344
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0432
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
8:30AM-10:30AM
Abstract Number: 0345
Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations
8:30AM-10:30AM
Abstract Number: 0137
Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
8:30AM-10:30AM
Abstract Number: 0326
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
8:30AM-10:30AM
Abstract Number: 0235
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
8:30AM-10:30AM
Abstract Number: 0038
Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs
8:30AM-10:30AM
Abstract Number: 0305
Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms
8:30AM-10:30AM
Abstract Number: 0172
Assessing Relevant Joints for Monitoring CPPD Diseases: A Systematic Literature Review of Imaging Techniques by the OMERACT Ultrasound – CPPD Subgroup
8:30AM-10:30AM
Abstract Number: 0319
Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States
8:30AM-10:30AM
Abstract Number: 0079
Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
8:30AM-10:30AM
Abstract Number: 0334
Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
8:30AM-10:30AM
Abstract Number: 0074
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
8:30AM-10:30AM
Abstract Number: 0085
Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
8:30AM-10:30AM
Abstract Number: 0082
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
8:30AM-10:30AM
Abstract Number: 0077
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0131
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0201
Australian Psoriatic Arthritis (PsA) Biologic Disease-modifying Antirheumatic Drug (bDMARD) Treatment Pathways Using Sankey Diagrams and Predictive Analysis: A Combined Australian Rheumatology Association Database (ARAD) and Pharmaceutical Benefits Scheme (PBS) Analysis
8:30AM-10:30AM
Abstract Number: 0044
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
8:30AM-10:30AM
Abstract Number: 0269
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0001
Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA Synthetase Family in Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0370
Awareness and Attitudes Regarding Axial Spondyloarthritis Among Primary Care Providers
8:30AM-10:30AM
Abstract Number: 0062
Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Microbiome Signature Besides Their Own Distinctive Profile
8:30AM-10:30AM
Abstract Number: 0214
Baseline Cam or Pincer Morphology Is Associated with Loss of Quantitative Joint Space Width at the Hip: The Johnston County Osteoarthritis Project
8:30AM-10:30AM
Abstract Number: 0277
Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0125
Body Mass Composition in Post-menopausal Women with Fibromyalgia: Preliminary Results from a Cross-sectional Monocentric Study
8:30AM-10:30AM
Abstract Number: 0171
Bone Erosions and Osteophytes in Premenopausal Women with Long-standing Rheumatoid Arthritis: Association with Systemic Bone Involvement Using HR-pQCT
8:30AM-10:30AM
Abstract Number: 0035
Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0367
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
8:30AM-10:30AM
Abstract Number: 0257
Can We Assess Disability in Juvenile Idiopathic Arthritis with Two Simple Questions? Results from the CAPRI Registry
8:30AM-10:30AM
Abstract Number: 0422
Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
8:30AM-10:30AM
Abstract Number: 0162
Cardiac Magnetic Resonance Imaging for Guiding Decision-making on Treatment Duration: Data from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
8:30AM-10:30AM
Abstract Number: 0083
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
8:30AM-10:30AM
Abstract Number: 0286
Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
8:30AM-10:30AM
Abstract Number: 0283
Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
8:30AM-10:30AM
Abstract Number: 0018
Caspase-8 Variant G Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Behavior
8:30AM-10:30AM
Abstract Number: 0429
Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
8:30AM-10:30AM
Abstract Number: 0049
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0307
Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?
8:30AM-10:30AM
Abstract Number: 0133
Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0094
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
8:30AM-10:30AM
Abstract Number: 0066
Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
8:30AM-10:30AM
Abstract Number: 0203
Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital
8:30AM-10:30AM
Abstract Number: 0020
Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells
8:30AM-10:30AM
Abstract Number: 0130
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
8:30AM-10:30AM
Abstract Number: 0431
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
8:30AM-10:30AM
Abstract Number: 0150
Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 0122
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 0092
Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City
8:30AM-10:30AM
Abstract Number: 0003
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
8:30AM-10:30AM
Abstract Number: 0135
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
8:30AM-10:30AM
Abstract Number: 0378
Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever
8:30AM-10:30AM
Abstract Number: 0294
Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
8:30AM-10:30AM
Abstract Number: 0256
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
8:30AM-10:30AM
Abstract Number: 0186
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON
8:30AM-10:30AM
Abstract Number: 0318
Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
8:30AM-10:30AM
Abstract Number: 0175
Correlation of Subclinical Synovitis with Juvenile Idiopathic Arthritis Outcome Measurements
8:30AM-10:30AM
Abstract Number: 0109
COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
8:30AM-10:30AM
Abstract Number: 0106
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
8:30AM-10:30AM
Abstract Number: 0116
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0084
COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
8:30AM-10:30AM
Abstract Number: 0013
Cyclin Dependent Kinase 4 and 6 Determine the Cytokine Responsiveness by Stabilizing JUN in Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0071
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
8:30AM-10:30AM
Abstract Number: 0059
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
8:30AM-10:30AM
Abstract Number: 0152
Deep Learning-Derived Chest Radiograph Scores in COVID-19 in Rheumatic Disease Patients versus General Population Comparators
8:30AM-10:30AM
Abstract Number: 0386
Delay to Diagnosis in Axial Spondyloarthritis: The Gap Is Closing, but Persistent Association with Severe Disease
8:30AM-10:30AM
Abstract Number: 0288
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
8:30AM-10:30AM
Abstract Number: 0297
Describing the Disease Burden of Primary Sjögren’s Syndrome Patients: Results from a Real-World Survey in the US
8:30AM-10:30AM
Abstract Number: 0142
Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center
8:30AM-10:30AM
Abstract Number: 0289
Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
8:30AM-10:30AM
Abstract Number: 0258
Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 0265
Development and Preliminary Acceptability of JIActiv, a Social Media-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 0420
Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0157
Development of a Deep Learning Algorithm for the Detection of Sacroiliitis on MRI in Patients with Active Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0063
Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
8:30AM-10:30AM
Abstract Number: 0244
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
8:30AM-10:30AM
Abstract Number: 0149
Development of Joint Effusion, Hyperperfusion and Enthesitis After One Hour of Age-and Gender Adjusted Weight Training
8:30AM-10:30AM
Abstract Number: 0163
Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
8:30AM-10:30AM
Abstract Number: 0425
Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study
8:30AM-10:30AM
Abstract Number: 0383
Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
8:30AM-10:30AM
Abstract Number: 0102
Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
8:30AM-10:30AM
Abstract Number: 0011
Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0166
Digital Extensor Paratenonitis Is Frequent in Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0170
Direct and Conditional Effects of Epicardial Adipose Tissue Volume on Coronary Plaque Progression in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0363
Disease Course and Disease Burden in Patients with Axial Spondyloarthritis: Results from 5-year Multicountry Prospective Observational Study
8:30AM-10:30AM
Abstract Number: 0164
Disrupted Executive Control Network Structural-Functional Integration Is Associated with Inferior Performance of Cognitive Switching Tasks in Patients with Systemic Lupus Erythematosus (SLE)
8:30AM-10:30AM
Abstract Number: 0216
Distribution of Medial Femur and Tibia Cartilage Volume Change over 48 Months on MRI: Comparison Among Kellgren-Lawrence Grades
8:30AM-10:30AM
Abstract Number: 0007
Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes
8:30AM-10:30AM
Abstract Number: 0313
Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?
8:30AM-10:30AM
Abstract Number: 0161
Does 18F-FDG-PET/MRI Add Metabolic Information to Anatomic Image in Childhood-onset Takayasu’s Arteritis Patients? A Multicenter Case Series
8:30AM-10:30AM
Abstract Number: 0364
Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Routine Care – 2-year Clinical and MRI Outcomes and Predictors of Successful Tapering
8:30AM-10:30AM
Abstract Number: 0177
Dual-Energy Computed Tomography Three Material Decomposition Improves the Sensitivity of Gout Detection
8:30AM-10:30AM
Abstract Number: 0153
Echogenic and Hypervascular Synovium Detected on Ultrasound Are Predictive of a Favorable Response After Intra-articular Corticosteroid Injection in Patients with Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0143
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0240
Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
8:30AM-10:30AM
Abstract Number: 0058
Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
8:30AM-10:30AM
Abstract Number: 0268
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0414
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
8:30AM-10:30AM
Abstract Number: 0188
Effect of Nintedanib on Categorical Changes in FVC in Patients with Progressive Fibrosing ILDs: Further Analyses of the INBUILD Trial
8:30AM-10:30AM
Abstract Number: 0403
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 0243
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
8:30AM-10:30AM
Abstract Number: 0224
Effects of Kinesiophobia and Physical Function on Physical Activity in Adults with Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0222
Effects of Multi-Joint Osteoarthritis Phenotypes on Self-Reported Physical Function over 3.5 Years: The Johnston County Osteoarthritis Project
8:30AM-10:30AM
Abstract Number: 0183
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
8:30AM-10:30AM
Abstract Number: 0108
Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
8:30AM-10:30AM
Abstract Number: 0039
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
8:30AM-10:30AM
Abstract Number: 0075
Endothelial Cell-activating Antibodies in COVID-19
8:30AM-10:30AM
Abstract Number: 0045
Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation
8:30AM-10:30AM
Abstract Number: 0350
EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
8:30AM-10:30AM
Abstract Number: 0396
Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial
8:30AM-10:30AM
Abstract Number: 0088
Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
8:30AM-10:30AM
Abstract Number: 0028
Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications
8:30AM-10:30AM
Abstract Number: 0316
Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials
8:30AM-10:30AM
Abstract Number: 0303
Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0194
Eye Opening: Use of IL-6 Inhibition in Non-Paraneoplastic Autoimmune Retinopathy
8:30AM-10:30AM
Abstract Number: 0361
Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
8:30AM-10:30AM
Abstract Number: 0360
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
8:30AM-10:30AM
Abstract Number: 0409
Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0392
Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort
8:30AM-10:30AM
Abstract Number: 0230
Fatigue and Inflammation in Rheumatoid Arthritis Are Already Disconnected Before Clinical Arthritis Develops
8:30AM-10:30AM
Abstract Number: 0233
Feasibility and Acceptability of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
8:30AM-10:30AM
Abstract Number: 0120
Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0069
First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
8:30AM-10:30AM
Abstract Number: 0242
FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
8:30AM-10:30AM
Abstract Number: 0099
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
8:30AM-10:30AM
Abstract Number: 0117
Flares Following Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
8:30AM-10:30AM
Abstract Number: 0078
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
8:30AM-10:30AM
Abstract Number: 0406
Gender Differences in Clinical Features and Outcomes of Systemic Sclerosis: Analysis of Reuma.pt/SSc Registry
8:30AM-10:30AM
Abstract Number: 0351
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
8:30AM-10:30AM
Abstract Number: 0368
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
8:30AM-10:30AM
Abstract Number: 0173
Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0068
Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
8:30AM-10:30AM
Abstract Number: 0061
Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
8:30AM-10:30AM
Abstract Number: 0144
Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada
8:30AM-10:30AM
Abstract Number: 0101
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
8:30AM-10:30AM
Abstract Number: 0024
Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
8:30AM-10:30AM
Abstract Number: 0262
High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0198
High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases
8:30AM-10:30AM
Abstract Number: 0226
High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
8:30AM-10:30AM
Abstract Number: 0369
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
8:30AM-10:30AM
Abstract Number: 0391
High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
8:30AM-10:30AM
Abstract Number: 0042
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0278
Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
8:30AM-10:30AM
Abstract Number: 0271
Higher Prevalence of Subclinical Atherosclerosis in the First Five Years of Rheumatoid Arthritis Diagnosis
8:30AM-10:30AM
Abstract Number: 0322
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
8:30AM-10:30AM
Abstract Number: 0310
Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0052
HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0132
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
8:30AM-10:30AM
Abstract Number: 0381
How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
8:30AM-10:30AM
Abstract Number: 0009
Humoral Immune Responses to SARS-CoV2 Infections and upon Vaccination Against SARS-CoV2
8:30AM-10:30AM
Abstract Number: 0206
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
8:30AM-10:30AM
Abstract Number: 0394
Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon
8:30AM-10:30AM
Abstract Number: 0037
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0051
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
8:30AM-10:30AM
Abstract Number: 0255
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
8:30AM-10:30AM
Abstract Number: 0160
Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing
8:30AM-10:30AM
Abstract Number: 0357
Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
8:30AM-10:30AM
Abstract Number: 0291
IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
8:30AM-10:30AM
Abstract Number: 0209
IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom
8:30AM-10:30AM
Abstract Number: 0032
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
8:30AM-10:30AM
Abstract Number: 0174
Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers
8:30AM-10:30AM
Abstract Number: 0034
Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients
8:30AM-10:30AM
Abstract Number: 0072
Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
8:30AM-10:30AM
Abstract Number: 0275
Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0234
Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
8:30AM-10:30AM
Abstract Number: 0372
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
8:30AM-10:30AM
Abstract Number: 0270
Impact of Macrophage Cholesterol Loading Capacity and Interactions with Treatments on Cardiovascular Risk and Coronary Atherosclerosis Burden in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0376
Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
8:30AM-10:30AM
Abstract Number: 0260
Impact on Caregivers of Patients with Juvenile Idiopathic Arthritis: A Hospital-based Study from India
8:30AM-10:30AM
Abstract Number: 0033
Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response
8:30AM-10:30AM
Abstract Number: 0180
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0179
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging Predicts Adverse Events in Patients with Autoimmune Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0148
Implementation of an Interprofessional Safety Check to Screen for Latent Tuberculosis at an Academic Tertiary Referral Rheumatology Clinic Increased Screening Rates Compared to Historical Levels
8:30AM-10:30AM
Abstract Number: 0146
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 0200
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
8:30AM-10:30AM
Abstract Number: 0019
Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate
8:30AM-10:30AM
Abstract Number: 0293
Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
8:30AM-10:30AM
Abstract Number: 0128
Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
8:30AM-10:30AM
Abstract Number: 0427
Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
8:30AM-10:30AM
Abstract Number: 0424
Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)
8:30AM-10:30AM
Abstract Number: 0192
Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry
8:30AM-10:30AM
Abstract Number: 0191
Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS) – 30-months Interim Analysis of the RELIANCE Registry
8:30AM-10:30AM
Abstract Number: 0050
Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0127
Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
8:30AM-10:30AM
Abstract Number: 0030
Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0430
Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
8:30AM-10:30AM
Abstract Number: 0219
Intra-Articular Mineralization on Knee CT and Risk of Cartilage Loss: The Multicenter Osteoarthritis Study
8:30AM-10:30AM
Abstract Number: 0023
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
8:30AM-10:30AM
Abstract Number: 0250
Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
8:30AM-10:30AM
Abstract Number: 0400
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
8:30AM-10:30AM
Abstract Number: 0401
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
8:30AM-10:30AM
Abstract Number: 0195
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
8:30AM-10:30AM
Abstract Number: 0029
JAK1 Regulates Autophagy and Reinforces the Inflammatory and Autoimmune Potentials in Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0259
JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
8:30AM-10:30AM
Abstract Number: 0008
Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
8:30AM-10:30AM
Abstract Number: 0264
Joint Acoustic Emissions as a Biomarker to Differentiate Between Active and Inactive Juvenile Idiopathic Arthritis via 2-stage Machine Learning Classifier
8:30AM-10:30AM
Abstract Number: 0017
Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
8:30AM-10:30AM
Abstract Number: 0060
Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0327
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
8:30AM-10:30AM
Abstract Number: 0410
Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019
8:30AM-10:30AM
Abstract Number: 0245
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
8:30AM-10:30AM
Abstract Number: 0190
Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry
8:30AM-10:30AM
Abstract Number: 0347
Longitudinal ANA Titers in SLE and ANA+ Controls
8:30AM-10:30AM
Abstract Number: 0418
Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0302
Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice
8:30AM-10:30AM
Abstract Number: 0014
Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up
8:30AM-10:30AM
Abstract Number: 0309
Lymphopenia and Leukopenia in Sjogren Syndrome
8:30AM-10:30AM
Abstract Number: 0040
M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects
8:30AM-10:30AM
Abstract Number: 0324
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
8:30AM-10:30AM
Abstract Number: 0246
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
8:30AM-10:30AM
Abstract Number: 0279
Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0181
Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
8:30AM-10:30AM
Abstract Number: 0280
Mast Cells Contribute to the Development of Lung Fibrosis via Inducing Myofibroblast Differentiation by TGF-β Production
8:30AM-10:30AM
Abstract Number: 0236
Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 0005
Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0067
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
8:30AM-10:30AM
Abstract Number: 0006
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
8:30AM-10:30AM
Abstract Number: 0027
Metabolomic Study of Rheumatoid Arthritis Using 1H Nuclear Magnetic Resonance (1H NMR)
8:30AM-10:30AM
Abstract Number: 0261
Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-systemic JIA Within the CARRA Registry
8:30AM-10:30AM
Abstract Number: 0057
Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab
8:30AM-10:30AM
Abstract Number: 0110
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
8:30AM-10:30AM
Abstract Number: 0105
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
8:30AM-10:30AM
Abstract Number: 0118
Multidimensional Phenotypes of Sleep Quality Using the Pittsburg Quality Sleep Index and Associations Among Sleep Dimensions and Symptoms in Women Diagnosed with Fibromyalgia
8:30AM-10:30AM
Abstract Number: 0208
Musculoskeletal Immune-Related Adverse Effects of Immune Checkpoint Inhibitors at a Single Site in a Hispanic Population in Puerto Rico
8:30AM-10:30AM
Abstract Number: 0435
Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071
8:30AM-10:30AM
Abstract Number: 0399
Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease
8:30AM-10:30AM
Abstract Number: 0352
Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
8:30AM-10:30AM
Abstract Number: 0328
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
8:30AM-10:30AM
Abstract Number: 0421
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
8:30AM-10:30AM
Abstract Number: 0417
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
8:30AM-10:30AM
Abstract Number: 0124
Nurse-supported Web-based Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain: An Effectiveness Trial
8:30AM-10:30AM
Abstract Number: 0436
Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
8:30AM-10:30AM
Abstract Number: 0426
Ocular Manifestations of ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0080
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
8:30AM-10:30AM
Abstract Number: 0249
Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0375
Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration
8:30AM-10:30AM
Abstract Number: 0228
Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research
8:30AM-10:30AM
Abstract Number: 0097
Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
8:30AM-10:30AM
Abstract Number: 0343
Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
8:30AM-10:30AM
Abstract Number: 0379
Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
8:30AM-10:30AM
Abstract Number: 0254
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 0317
Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study
8:30AM-10:30AM
Abstract Number: 0359
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
8:30AM-10:30AM
Abstract Number: 0098
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
8:30AM-10:30AM
Abstract Number: 0103
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
8:30AM-10:30AM
Abstract Number: 0263
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
8:30AM-10:30AM
Abstract Number: 0398
Performance of ACR CRISS Score and Revised ACR CRISS Response in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc) in Which Background Immunosuppressive Therapies (bIST) Were Allowed
8:30AM-10:30AM
Abstract Number: 0349
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
8:30AM-10:30AM
Abstract Number: 0320
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0335
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
8:30AM-10:30AM
Abstract Number: 0404
Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
8:30AM-10:30AM
Abstract Number: 0056
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
8:30AM-10:30AM
Abstract Number: 0411
Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
8:30AM-10:30AM
Abstract Number: 0416
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0185
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
8:30AM-10:30AM
Abstract Number: 0184
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
8:30AM-10:30AM
Abstract Number: 0419
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
8:30AM-10:30AM
Abstract Number: 0076
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
8:30AM-10:30AM
Abstract Number: 0388
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0387
Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases
8:30AM-10:30AM
Abstract Number: 0413
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
8:30AM-10:30AM
Abstract Number: 0070
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
8:30AM-10:30AM
Abstract Number: 0290
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
8:30AM-10:30AM
Abstract Number: 0126
Prevalence of Dyslipidemia in Fibromyalgia: A Single Center Case Control Study from South India
8:30AM-10:30AM
Abstract Number: 0225
Prevalence of Sexual Dysfunction and Depression in German Patients with Psoriasis and Psoriatic Arthritis – Results of the PIPPA Study
8:30AM-10:30AM
Abstract Number: 0332
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
8:30AM-10:30AM
Abstract Number: 0412
Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
8:30AM-10:30AM
Abstract Number: 0064
Prevalence, Incidence and Predictor Features of Uveitis in Spondyloarthritis in a Canadian Cohort
8:30AM-10:30AM
Abstract Number: 0312
Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0314
PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0248
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
8:30AM-10:30AM
Abstract Number: 0434
Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
8:30AM-10:30AM
Abstract Number: 0241
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
8:30AM-10:30AM
Abstract Number: 0046
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
8:30AM-10:30AM
Abstract Number: 0267
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
8:30AM-10:30AM
Abstract Number: 0276
Pulse Pressure as a Predictor of Carotid Plaque in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0213
Quantitative Assessment of Volumetric Change in Hip Effusion Using Artificial Intelligence in Patients with Osteoarthritis of the Hip
8:30AM-10:30AM
Abstract Number: 0272
RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
8:30AM-10:30AM
Abstract Number: 0329
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
8:30AM-10:30AM
Abstract Number: 0342
RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0199
Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases
8:30AM-10:30AM
Abstract Number: 0337
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
8:30AM-10:30AM
Abstract Number: 0113
Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
8:30AM-10:30AM
Abstract Number: 0129
Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
8:30AM-10:30AM
Abstract Number: 0231
Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool
8:30AM-10:30AM
Abstract Number: 0220
Relation of Knee Extensor Power to Worsening Cartilage Damage in the Knee: The MOST Study
8:30AM-10:30AM
Abstract Number: 0010
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
8:30AM-10:30AM
Abstract Number: 0167
Reliability of a Novel Pediatric Joint-Specific Scoring System for the Elbow, Wrist and Finger Joints
8:30AM-10:30AM
Abstract Number: 0304
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
8:30AM-10:30AM
Abstract Number: 0405
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0115
Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020
8:30AM-10:30AM
Abstract Number: 0015
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
8:30AM-10:30AM
Abstract Number: 0253
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
8:30AM-10:30AM
Abstract Number: 0145
Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
8:30AM-10:30AM
Abstract Number: 0095
Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
8:30AM-10:30AM
Abstract Number: 0284
Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
8:30AM-10:30AM
Abstract Number: 0285
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
8:30AM-10:30AM
Abstract Number: 0204
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
8:30AM-10:30AM
Abstract Number: 0111
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
8:30AM-10:30AM
Abstract Number: 0395
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
8:30AM-10:30AM
Abstract Number: 0323
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 0252
Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 0397
Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0187
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
8:30AM-10:30AM
Abstract Number: 0100
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
8:30AM-10:30AM
Abstract Number: 0300
Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0002
Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
8:30AM-10:30AM
Abstract Number: 0086
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review
8:30AM-10:30AM
Abstract Number: 0089
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
8:30AM-10:30AM
Abstract Number: 0373
Self-monitoring of Disease Activity with a Smartphone App Is Feasible in Routine Clinical Management of Patients with Axial Spondyloarthritis – a Proof of Concept Study
8:30AM-10:30AM
Abstract Number: 0237
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
8:30AM-10:30AM
Abstract Number: 0371
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
8:30AM-10:30AM
Abstract Number: 0176
Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease
8:30AM-10:30AM
Abstract Number: 0321
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
8:30AM-10:30AM
Abstract Number: 0330
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
8:30AM-10:30AM
Abstract Number: 0338
Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0393
Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
8:30AM-10:30AM
Abstract Number: 0299
Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios
8:30AM-10:30AM
Abstract Number: 0165
Shear-Wave Elastography Evaluation of Major Salivary Glands and Correlation with B-mode Findings in Patients with Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0380
Sick Leave and Its Predictors in Early Axial Spondyloarthritis: The Role of Clinical and Socioeconomic Factors. Five-year Data from the DESIR Cohort
8:30AM-10:30AM
Abstract Number: 0382
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0315
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
8:30AM-10:30AM
Abstract Number: 0308
Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0353
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0016
Structural and Functional Neurobiological Alterations of Salience and Sensorimotor Networks in Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 0159
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
8:30AM-10:30AM
Abstract Number: 0090
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
8:30AM-10:30AM
Abstract Number: 0197
Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series
8:30AM-10:30AM
Abstract Number: 0292
Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0053
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease
8:30AM-10:30AM
Abstract Number: 0026
Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)
8:30AM-10:30AM
Abstract Number: 0218
Synovitis Does Not Mediate the Relationship Between Body Mass Index and Progression of Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
8:30AM-10:30AM
Abstract Number: 0134
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
8:30AM-10:30AM
Abstract Number: 0043
Takinib Inhibits IL-1β-Induced Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in Human Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0189
Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis
8:30AM-10:30AM
Abstract Number: 0054
TCR Immune Profiling of Patients with Psoriatic Disease
8:30AM-10:30AM
Abstract Number: 0182
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0156
Tenosynovitis Detected by Power Doppler Ultrasound: A Differential Feature of Patients with Seronegative Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0155
The Additional Value of MRI in Diagnosis of Rheumatoid Arthritis in Undifferentiated Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0223
The Association of Clinical and Structural Knee Osteoarthritis with Physical Activity in the Middle-aged Population: The Netherlands Epidemiology of Obesity Study
8:30AM-10:30AM
Abstract Number: 0093
The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities
8:30AM-10:30AM
Abstract Number: 0346
The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
8:30AM-10:30AM
Abstract Number: 0298
The Clinical Phenotype of Isolated Ocular and Oral Dryness in Sjogren Syndrome, Fulfilling the 2016 ACR-EULAR Classification Criteria
8:30AM-10:30AM
Abstract Number: 0407
The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0385
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0022
The Effects of MAA-Modified and/or Citrullinated Proteins on Calcium Influx and Peptidyl Arginine Deiminase (PAD) Expression in Macrophage
8:30AM-10:30AM
Abstract Number: 0229
The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education
8:30AM-10:30AM
Abstract Number: 0121
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
8:30AM-10:30AM
Abstract Number: 0296
The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US
8:30AM-10:30AM
Abstract Number: 0232
The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients with Active PsA
8:30AM-10:30AM
Abstract Number: 0238
The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0336
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
8:30AM-10:30AM
Abstract Number: 0158
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0025
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0036
The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects
8:30AM-10:30AM
Abstract Number: 0348
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
8:30AM-10:30AM
Abstract Number: 0217
The OMERACT Knee Inflammation MRI Scoring System: Validation of Quantitative Methodologies and Tri-compartmental Overlays by Comparison with the MRI Osteoarthritis Knee Score
8:30AM-10:30AM
Abstract Number: 0377
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
8:30AM-10:30AM
Abstract Number: 0266
The Psychosocial Impact of the COVID-19 Pandemic on the Rheumatology Patient Experience
8:30AM-10:30AM
Abstract Number: 0356
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
8:30AM-10:30AM
Abstract Number: 0114
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 0096
The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
8:30AM-10:30AM
Abstract Number: 0140
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0247
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
8:30AM-10:30AM
Abstract Number: 0081
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
8:30AM-10:30AM
Abstract Number: 0055
Time Course of Intestinal Permeability and Intestinal Inflammation in Rat Adjuvant-induced Arthritis
8:30AM-10:30AM
Abstract Number: 0087
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
8:30AM-10:30AM
Abstract Number: 0193
Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, Double Blind, Placebo-controlled Phase II Study
8:30AM-10:30AM
Abstract Number: 0139
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
8:30AM-10:30AM
Abstract Number: 0207
Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital
8:30AM-10:30AM
Abstract Number: 0138
Treatment with Adalimumab in Patients with Chronic Inflammatory Rheumatic Diseases: A Study of Treatment Trajectories on a Patient Level in Clinical Practice
8:30AM-10:30AM
Abstract Number: 0339
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 0221
Trunk Movement Compensation Is Associated with Physical Performance Measures and Fatigue Deficits in Hip Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0311
Ultra High‐frequency Ultrasound (UHFUS) of Labial Glands in Primary Sjögren’s Syndrome: Serological and Histological Correlations
8:30AM-10:30AM
Abstract Number: 0215
Ultrasonographic Assessment of Knee Osteoarthritis and Its Agreement with Radiography
8:30AM-10:30AM
Abstract Number: 0169
Ultrasonography of Auricular Cartilage Is a Useful Tool for Diagnosing and Monitoring Disease Activity in Relapsing Polychondritis
8:30AM-10:30AM
Abstract Number: 0004
Unappreciated Systemic Metabolic Functions of the Canonical B Cell Cytokines, BAFF and APRIL: Regulation of Lipolysis and Non-shivering Thermogenesis and Protection from Obesogenic Diet Induced Weight Gain
8:30AM-10:30AM
Abstract Number: 0136
Underutilization of Mental Health Services in a Busy Tertiary Care Rheumatology Facility
8:30AM-10:30AM
Abstract Number: 0021
Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA
8:30AM-10:30AM
Abstract Number: 0212
Unsupervised Clustering of Histology and Ultrasound Scores Identifies Osteoarthritis Subtypes
8:30AM-10:30AM
Abstract Number: 0281
Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0211
Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database
8:30AM-10:30AM
Abstract Number: 0340
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0331
Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
8:30AM-10:30AM
Abstract Number: 0423
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0433
Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
8:30AM-10:30AM
Abstract Number: 0389
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
8:30AM-10:30AM
Abstract Number: 0151
Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis
8:30AM-10:30AM
Abstract Number: 0210
Using Machine Learning to Predict Medial Knee Cartilage Worsening over 2 Years Using Gait and Physical Activity: The MOST Study
8:30AM-10:30AM
Abstract Number: 0415
Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis
8:30AM-10:30AM
Abstract Number: 0355
Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0154
Utilization of Magnetic Resonance Imaging in Early Rheumatoid Arthritis: Results from a Population-based Cohort (1999-2014)
8:30AM-10:30AM
Abstract Number: 0390
Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
8:30AM-10:30AM
Abstract Number: 0091
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
8:30AM-10:30AM
Abstract Number: 0333
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
8:30AM-10:30AM
Abstract Number: 0374
Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study
8:30AM-10:30AM
Abstract Number: 0202
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
8:30AM-10:30AM
Abstract Number: 0041
Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0123
Vestibulocortical Stimulation with Caloric Irrigation Reduces Pain and Improves Subjective Well-Being in Fibromyalgia: An Open-Label Pilot Trial
8:30AM-10:30AM
Abstract Number: 0295
Weight History and Associations with Cardiovascular Risk in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0402
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
8:30AM-10:30AM
Abstract Number: 0141
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
8:30AM-10:30AM
Abstract Number: 0366
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
8:30AM-10:30AM
Abstract Number: 0239
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
8:30AM-10:30AM
Abstract Number: 0358
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
8:30AM-10:30AM
Abstract Number: 0227
Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
8:30AM-10:30AM
Abstract Number: 0119
Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients
9:00AM-9:15AM
Abstract Number: 0441
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
9:00AM-9:15AM
Abstract Number: 0437
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
9:15AM-9:30AM
Abstract Number: 0442
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
9:15AM-9:30AM
Abstract Number: 0438
Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors Based on the FDA Adverse Event Reporting System
9:30AM-9:45AM
Abstract Number: 0449
Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
9:30AM-9:45AM
Abstract Number: 0439
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
9:30AM-9:45AM
Abstract Number: 0443
Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
9:30AM-9:45AM
Abstract Number: 0445
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
9:45AM-10:00AM
Abstract Number: 0440
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
9:45AM-10:00AM
Abstract Number: 0446
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
9:45AM-10:00AM
Abstract Number: 0444
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
9:45AM-10:00AM
Abstract Number: 0450
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
10:00AM-10:15AM
Abstract Number: 0447
Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
10:00AM-10:15AM
Abstract Number: 0451
Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
10:15AM-10:30AM
Abstract Number: 0448
Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as Predictor of Incident Fracture in Rheumatic Disease Patients on Long-term Glucocorticoid- a Five-year Longitudinal Study
10:15AM-10:30AM
Abstract Number: 0452
Total-Body 18F-FDG PET/CT Imaging: A Tool for Diagnosis and Quantifying Inflammatory Burden of Psoriatic Arthritis
10:30AM-10:45AM
Abstract Number: 0462
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
10:30AM-10:45AM
Abstract Number: 0458
Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology
10:30AM-10:45AM
Abstract Number: 0466
Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica
10:45AM-11:00AM
Abstract Number: 0467
Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)
10:45AM-11:00AM
Abstract Number: 0459
CCN1: An Angiogenic Actor Implicated in the Structural Damages of Rheumatoid Arthritis
10:45AM-11:00AM
Abstract Number: 0453
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Integrated Results from 2 Phase 3, Randomized, Double-blind Clinical Trials for CsDMARD-IR and Bio-IR Patients
10:45AM-11:00AM
Abstract Number: 0463
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
11:00AM-11:15AM
Abstract Number: 0474
Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
11:00AM-11:15AM
Abstract Number: 0468
During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia
11:00AM-11:15AM
Abstract Number: 0470
Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
11:00AM-11:15AM
Abstract Number: 0454
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
11:00AM-11:15AM
Abstract Number: 0460
Single-cell Profiling of B and T Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
11:00AM-11:15AM
Abstract Number: 0464
The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
11:15AM-11:30AM
Abstract Number: 0455
Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients
11:15AM-11:30AM
Abstract Number: 0465
Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
11:15AM-11:30AM
Abstract Number: 0469
Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial
11:15AM-11:30AM
Abstract Number: 0461
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
11:15AM-11:30AM
Abstract Number: 0475
Quantitative Analysis of Gender and Racial Disparities in Randomized Controlled Trials of Fibromyalgia
11:15AM-11:30AM
Abstract Number: 0471
Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus
11:30AM-11:45AM
Abstract Number: 0472
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
11:30AM-11:45AM
Abstract Number: 0476
Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
11:30AM-11:45AM
Abstract Number: 0456
Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus
11:45AM-12:00PM
Abstract Number: 0473
Disease-Associated Microglia Are Implicated in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
11:45AM-12:00PM
Abstract Number: 0457
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
11:45AM-12:00PM
Abstract Number: 0477
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
2:00PM-2:15PM
Abstract Number: 0488
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
2:00PM-2:15PM
Abstract Number: 0478
Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method
2:00PM-2:15PM
Abstract Number: 0484
RheumMadness: Creating an Online Community of Inquiry
2:15PM-2:30PM
Abstract Number: 0479
A Novel Semi-automated Classifier of Radiographic Hip Osteoarthritis on DXA Scans Is Strongly Predictive of Pain, Clinical Diagnosis and Joint Replacement: Findings from 40,000 Participants in UK Biobank
2:15PM-2:30PM
Abstract Number: 0489
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
2:15PM-2:30PM
Abstract Number: 0485
The Impact of COVID-19 on Rheumatology Trainee Health and Wellbeing: Results from the COVID-19 Global Rheumatology Alliance Trainee Survey
2:30PM-2:45PM
Abstract Number: 0486
A Practical Approach to Competency-based Evaluations and Milestone Mapping for Adult Rheumatology Fellowship Programs
2:30PM-2:45PM
Abstract Number: 0490
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
2:30PM-2:45PM
Abstract Number: 0480
Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
2:45PM-3:00PM
Abstract Number: 0487
A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors
2:45PM-3:00PM
Abstract Number: 0491
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
2:45PM-3:00PM
Abstract Number: 0481
The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study
3:00PM-3:15PM
Abstract Number: 0482
Metformin Use Reduces the Risk of Developing Osteoarthritis: A Propensity Score Matching Study
3:15PM-3:30PM
Abstract Number: 0483
Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
3:30PM-3:45PM
Abstract Number: 0502
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
3:30PM-3:45PM
Abstract Number: 0492
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
3:30PM-3:45PM
Abstract Number: 0496
Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
3:45PM-4:00PM
Abstract Number: 0503
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
3:45PM-4:00PM
Abstract Number: 0497
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
3:45PM-4:00PM
Abstract Number: 0493
Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study
4:00PM-4:15PM
Abstract Number: 0498
Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
4:00PM-4:15PM
Abstract Number: 0504
Longitudinal Patterns of Vascular Inflammation in Large-vessel Vasculitis
4:00PM-4:15PM
Abstract Number: 0494
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
4:15PM-4:30PM
Abstract Number: 0499
Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
4:15PM-4:30PM
Abstract Number: 0495
Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
4:15PM-4:30PM
Abstract Number: 0505
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
4:30PM-4:45PM
Abstract Number: 0500
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
4:30PM-4:45PM
Abstract Number: 0506
Transcriptomic Changes Induced by Mavrilimumab versus Tocilizumab in ex-vivo Cultured Arteries from Patients with Giant-cell Arteritis
4:45PM-5:00PM
Abstract Number: 0501
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
4:45PM-5:00PM
Abstract Number: 0507
Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 0674
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 0600
A Cohort Study of Retention in Ambulatory Lupus Care Among Medicare Patients with SLE-related Hospitalizations
8:30AM-10:30AM
Abstract Number: 0853
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
8:30AM-10:30AM
Abstract Number: 0729
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
8:30AM-10:30AM
Abstract Number: 0570
A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
8:30AM-10:30AM
Abstract Number: 0733
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
8:30AM-10:30AM
Abstract Number: 0845
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
8:30AM-10:30AM
Abstract Number: 0867
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0847
A Psychometric Analysis of the Self-Efficacy for Managing Chronic Disease Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
8:30AM-10:30AM
Abstract Number: 0819
A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
8:30AM-10:30AM
Abstract Number: 0805
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
8:30AM-10:30AM
Abstract Number: 0656
A Survey Based Descriptive Study to Assess the Quality of Sleep in Rheumatic Patients
8:30AM-10:30AM
Abstract Number: 0658
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0667
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
8:30AM-10:30AM
Abstract Number: 0608
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients
8:30AM-10:30AM
Abstract Number: 0647
Adherence to Hydroxychloroquine Dosing and Teleretinal Screening: Assessment and Quality Improvement
8:30AM-10:30AM
Abstract Number: 0653
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
8:30AM-10:30AM
Abstract Number: 0789
Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0685
Adipokines and Loss of Lean Mass Among Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0897
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0569
All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
8:30AM-10:30AM
Abstract Number: 0582
Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults
8:30AM-10:30AM
Abstract Number: 0825
An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial
8:30AM-10:30AM
Abstract Number: 0731
An Open-Label Study to Evaluate the Effect of Intra-articular Triamcinolone Acetonide Extended Release on Patients with Baseline Synovitis and Osteoarthritis of the Knee
8:30AM-10:30AM
Abstract Number: 0816
Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
8:30AM-10:30AM
Abstract Number: 0879
Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems
8:30AM-10:30AM
Abstract Number: 0704
Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0696
Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study
8:30AM-10:30AM
Abstract Number: 0876
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
8:30AM-10:30AM
Abstract Number: 0652
Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic
8:30AM-10:30AM
Abstract Number: 0851
Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0746
Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?
8:30AM-10:30AM
Abstract Number: 0794
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0812
Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 0751
Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
8:30AM-10:30AM
Abstract Number: 0905
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
8:30AM-10:30AM
Abstract Number: 0657
Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare
8:30AM-10:30AM
Abstract Number: 0681
Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes
8:30AM-10:30AM
Abstract Number: 0654
Assessing Provider Knowledge and Opinions of the 2017 Guidelines for Perioperative Management of Antirheumatic Medications in a Single Academic Center
8:30AM-10:30AM
Abstract Number: 0637
Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0741
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
8:30AM-10:30AM
Abstract Number: 0749
Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
8:30AM-10:30AM
Abstract Number: 0580
Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women
8:30AM-10:30AM
Abstract Number: 0611
Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists
8:30AM-10:30AM
Abstract Number: 0717
Association of Fatigue with Disease Activity in Myositis
8:30AM-10:30AM
Abstract Number: 0877
Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
8:30AM-10:30AM
Abstract Number: 0787
Association of Hemoglobin Levels and Radiographic Progression in the BRASS Registry
8:30AM-10:30AM
Abstract Number: 0590
Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
8:30AM-10:30AM
Abstract Number: 0887
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
8:30AM-10:30AM
Abstract Number: 0707
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 0889
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
8:30AM-10:30AM
Abstract Number: 0857
Association of Telomere Length with Phenotypic Frailty in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0860
Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis
8:30AM-10:30AM
Abstract Number: 0564
Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0576
Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0855
Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 0547
Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells
8:30AM-10:30AM
Abstract Number: 0778
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0848
Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models
8:30AM-10:30AM
Abstract Number: 0603
Barriers and Potential Solutions in the Recruitment and Retention of Older Patients in Clinical Trials – Lessons Learned from Six Large Multi-center Randomized Controlled Trials
8:30AM-10:30AM
Abstract Number: 0766
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
8:30AM-10:30AM
Abstract Number: 0934
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-Radiographic Axial Spondylarthritis Patients Through 52 Weeks: Data from 3 Phase III, Randomized, Controlled Trials
8:30AM-10:30AM
Abstract Number: 0821
Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
8:30AM-10:30AM
Abstract Number: 0807
Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
8:30AM-10:30AM
Abstract Number: 0540
Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0922
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
8:30AM-10:30AM
Abstract Number: 0818
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
8:30AM-10:30AM
Abstract Number: 0915
Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0817
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
8:30AM-10:30AM
Abstract Number: 0573
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
8:30AM-10:30AM
Abstract Number: 0870
Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
8:30AM-10:30AM
Abstract Number: 0852
Bone Marrow Lesion Segmentation Using Synthetic Data and Deep Learning Models
8:30AM-10:30AM
Abstract Number: 0754
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
8:30AM-10:30AM
Abstract Number: 0625
Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes
8:30AM-10:30AM
Abstract Number: 0679
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
8:30AM-10:30AM
Abstract Number: 0708
Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
8:30AM-10:30AM
Abstract Number: 0621
Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers
8:30AM-10:30AM
Abstract Number: 0703
CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis
8:30AM-10:30AM
Abstract Number: 0868
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
8:30AM-10:30AM
Abstract Number: 0609
Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
8:30AM-10:30AM
Abstract Number: 0866
Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
8:30AM-10:30AM
Abstract Number: 0589
Circulating Adipokines and Risk of Rheumatoid Arthritis in Women
8:30AM-10:30AM
Abstract Number: 0572
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
8:30AM-10:30AM
Abstract Number: 0873
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
8:30AM-10:30AM
Abstract Number: 0699
Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
8:30AM-10:30AM
Abstract Number: 0687
Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0700
Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review
8:30AM-10:30AM
Abstract Number: PP06
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
8:30AM-10:30AM
Abstract Number: 0577
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
8:30AM-10:30AM
Abstract Number: 0938
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
8:30AM-10:30AM
Abstract Number: 0834
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
8:30AM-10:30AM
Abstract Number: 0839
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
8:30AM-10:30AM
Abstract Number: 0899
Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
8:30AM-10:30AM
Abstract Number: 0869
Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0617
Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0671
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
8:30AM-10:30AM
Abstract Number: 0854
Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0832
Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0568
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
8:30AM-10:30AM
Abstract Number: 0739
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
8:30AM-10:30AM
Abstract Number: 0636
Contraceptive and Pre-conception Counseling in an Academic Rheumatology Practice: A Needs Assessment to Identify Gaps in Care
8:30AM-10:30AM
Abstract Number: 0793
Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
8:30AM-10:30AM
Abstract Number: 0529
COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 0806
Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
8:30AM-10:30AM
Abstract Number: 0635
Correlation Between Provider Documentation and Patient Experience with Contraceptive Counseling in an Academic Rheumatology Practice
8:30AM-10:30AM
Abstract Number: 0634
Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0882
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0646
Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study
8:30AM-10:30AM
Abstract Number: 0904
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0736
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
8:30AM-10:30AM
Abstract Number: 0775
Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0785
Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness
8:30AM-10:30AM
Abstract Number: 0655
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0890
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
8:30AM-10:30AM
Abstract Number: 0697
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
8:30AM-10:30AM
Abstract Number: 0886
Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample
8:30AM-10:30AM
Abstract Number: 0567
Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
8:30AM-10:30AM
Abstract Number: 0532
Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
8:30AM-10:30AM
Abstract Number: 0761
Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0524
Development of Biomarker Models to Identify HLA-related Microbiome Associations in Anti-Ro+ Mothers of Children with Neonatal Lupus
8:30AM-10:30AM
Abstract Number: 0676
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
8:30AM-10:30AM
Abstract Number: 0826
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
8:30AM-10:30AM
Abstract Number: 0714
Diagnostic Accuracy of Electromyogram for Myositis
8:30AM-10:30AM
Abstract Number: 0651
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
8:30AM-10:30AM
Abstract Number: 0786
Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with Inflammatory Arthritis on Treatment with Methotrexate (MTX)
8:30AM-10:30AM
Abstract Number: 0598
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
8:30AM-10:30AM
Abstract Number: 0757
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
8:30AM-10:30AM
Abstract Number: 0800
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
8:30AM-10:30AM
Abstract Number: 0663
Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout
8:30AM-10:30AM
Abstract Number: 0827
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
8:30AM-10:30AM
Abstract Number: 0693
Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
8:30AM-10:30AM
Abstract Number: 0916
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
8:30AM-10:30AM
Abstract Number: 0888
Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
8:30AM-10:30AM
Abstract Number: 0604
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
8:30AM-10:30AM
Abstract Number: 0587
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
8:30AM-10:30AM
Abstract Number: 0626
Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
8:30AM-10:30AM
Abstract Number: 0902
Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
8:30AM-10:30AM
Abstract Number: 0864
Does Obesity Affect Disease Activity Outcomes in Systemic Lupus Erythematosus?
8:30AM-10:30AM
Abstract Number: 0672
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
8:30AM-10:30AM
Abstract Number: 0724
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
8:30AM-10:30AM
Abstract Number: 0911
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
8:30AM-10:30AM
Abstract Number: 0516
Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block
8:30AM-10:30AM
Abstract Number: PP04
Dual Roles: Thriving with SLE as a Medical Student
8:30AM-10:30AM
Abstract Number: 0530
Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
8:30AM-10:30AM
Abstract Number: 0931
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0801
Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0669
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
8:30AM-10:30AM
Abstract Number: 0881
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
8:30AM-10:30AM
Abstract Number: 0858
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
8:30AM-10:30AM
Abstract Number: 0750
Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Questionnaires 12 and 9: Analysis of a Phase 2 Study of Active Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0661
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
8:30AM-10:30AM
Abstract Number: 0921
Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
8:30AM-10:30AM
Abstract Number: 0930
Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
8:30AM-10:30AM
Abstract Number: 0599
Effectiveness of a Provider Led Intervention on Medication Adherence in an Urban Lupus Clinic
8:30AM-10:30AM
Abstract Number: 0588
Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
8:30AM-10:30AM
Abstract Number: 0833
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
8:30AM-10:30AM
Abstract Number: 0560
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
8:30AM-10:30AM
Abstract Number: 0935
Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0912
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
8:30AM-10:30AM
Abstract Number: 0924
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
8:30AM-10:30AM
Abstract Number: 0917
Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA
8:30AM-10:30AM
Abstract Number: 0725
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
8:30AM-10:30AM
Abstract Number: 0737
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
8:30AM-10:30AM
Abstract Number: 0561
Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
8:30AM-10:30AM
Abstract Number: 0622
Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
8:30AM-10:30AM
Abstract Number: 0610
Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System
8:30AM-10:30AM
Abstract Number: 0770
Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort
8:30AM-10:30AM
Abstract Number: 0859
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0908
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
8:30AM-10:30AM
Abstract Number: 0937
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
8:30AM-10:30AM
Abstract Number: 0782
Examining the Association of Socioenvironmental Factors with Depression and Anxiety Symptoms Among Youth with Childhood-Onset Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0684
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
8:30AM-10:30AM
Abstract Number: 0514
Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0936
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
8:30AM-10:30AM
Abstract Number: PP09
Family Planning while Living with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0510
Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes
8:30AM-10:30AM
Abstract Number: PP05
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
8:30AM-10:30AM
Abstract Number: 0928
Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0836
Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0698
Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
8:30AM-10:30AM
Abstract Number: 0644
Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems
8:30AM-10:30AM
Abstract Number: 0542
Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis
8:30AM-10:30AM
Abstract Number: 0592
Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
8:30AM-10:30AM
Abstract Number: 0884
Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0776
Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations
8:30AM-10:30AM
Abstract Number: 0522
Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients
8:30AM-10:30AM
Abstract Number: 0521
Genome-Wide DNA Methylation and Gene Expression Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0694
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
8:30AM-10:30AM
Abstract Number: 0742
Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet
8:30AM-10:30AM
Abstract Number: 0682
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
8:30AM-10:30AM
Abstract Number: 0680
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
8:30AM-10:30AM
Abstract Number: 0880
Health Information Use by SLE Patients Pre and During COVID-19
8:30AM-10:30AM
Abstract Number: 0894
Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
8:30AM-10:30AM
Abstract Number: 0670
Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone
8:30AM-10:30AM
Abstract Number: 0780
High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0584
High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0715
High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0628
Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study
8:30AM-10:30AM
Abstract Number: 0909
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
8:30AM-10:30AM
Abstract Number: 0606
How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines
8:30AM-10:30AM
Abstract Number: PP07
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 0578
Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
8:30AM-10:30AM
Abstract Number: 0533
Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase
8:30AM-10:30AM
Abstract Number: 0856
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0553
IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study
8:30AM-10:30AM
Abstract Number: 0712
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
8:30AM-10:30AM
Abstract Number: 0835
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
8:30AM-10:30AM
Abstract Number: 0692
Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications
8:30AM-10:30AM
Abstract Number: 0690
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
8:30AM-10:30AM
Abstract Number: 0925
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
8:30AM-10:30AM
Abstract Number: 0605
Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
8:30AM-10:30AM
Abstract Number: 0632
Impact of COVID-19 and Telehealth on RAPID3 Screening in an Academic Rheumatology Practice: Identifying Disparities in Care
8:30AM-10:30AM
Abstract Number: 0640
Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
8:30AM-10:30AM
Abstract Number: 0815
Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID
8:30AM-10:30AM
Abstract Number: 0813
Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
8:30AM-10:30AM
Abstract Number: 0648
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
8:30AM-10:30AM
Abstract Number: 0639
Improving Pre-biologic Infection Screening Using a Best Practice Alert in Electronic Health Records
8:30AM-10:30AM
Abstract Number: 0638
Improving Safety in Rheumatology Patients by Closing Pre-screening Laboratory Care Gaps
8:30AM-10:30AM
Abstract Number: 0660
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
8:30AM-10:30AM
Abstract Number: 0689
Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
8:30AM-10:30AM
Abstract Number: 0565
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
8:30AM-10:30AM
Abstract Number: 0719
Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0627
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
8:30AM-10:30AM
Abstract Number: 0918
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
8:30AM-10:30AM
Abstract Number: 0802
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
8:30AM-10:30AM
Abstract Number: 0920
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
8:30AM-10:30AM
Abstract Number: 0562
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
8:30AM-10:30AM
Abstract Number: 0895
Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0546
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0528
Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
8:30AM-10:30AM
Abstract Number: 0752
Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target
8:30AM-10:30AM
Abstract Number: 0623
Intervention to Improve SLE Medication Adherence
8:30AM-10:30AM
Abstract Number: 0728
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
8:30AM-10:30AM
Abstract Number: 0556
Investigating the Heterogeneity of Skin Macrophages in Systemic Scleroderma
8:30AM-10:30AM
Abstract Number: 0878
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
8:30AM-10:30AM
Abstract Number: 0686
Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study
8:30AM-10:30AM
Abstract Number: 0620
Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
8:30AM-10:30AM
Abstract Number: 0678
Is There a Difference in Self-reported Flare Frequency Between Men and Women?
8:30AM-10:30AM
Abstract Number: 0919
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0773
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0726
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
8:30AM-10:30AM
Abstract Number: 0593
Labour Force Participation Among Individuals with Osteoarthritis, Rheumatoid Arthritis/Other Arthritis Types, or with Joint Symptoms but Without a Diagnosis: An Age-Stratified Population-Based Study
8:30AM-10:30AM
Abstract Number: 0872
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
8:30AM-10:30AM
Abstract Number: 0520
Leukocyte Immunoglobulin-like Receptor A3 Facilitates Neutrophil Extracellular Trap Formation in TLR7-induced Lupus Mice
8:30AM-10:30AM
Abstract Number: PP02
Leveraging Digital Health Tracking to Improve Arthritis Management
8:30AM-10:30AM
Abstract Number: 0822
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
8:30AM-10:30AM
Abstract Number: 0552
Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0781
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
8:30AM-10:30AM
Abstract Number: 0913
Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
8:30AM-10:30AM
Abstract Number: 0828
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
8:30AM-10:30AM
Abstract Number: 0901
Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0709
Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0808
Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0865
Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study
8:30AM-10:30AM
Abstract Number: 0595
Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
8:30AM-10:30AM
Abstract Number: 0534
Lymphatic Dysfunction in Murine Lupus Photosensitivity
8:30AM-10:30AM
Abstract Number: 0765
Male Juvenile Systemic Sclerosis Patients Have More Severe Disease: Results from the International Juvenile Scleroderma Inception Cohort
8:30AM-10:30AM
Abstract Number: 0716
Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis
8:30AM-10:30AM
Abstract Number: 0713
MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients
8:30AM-10:30AM
Abstract Number: 0744
MDHAQ (Multidimensional Health Assessment Questionnaire) and PROMIS-29 (patient-reported Outcomes Measurement Information System) Domains for Physical Function, Pain, Fatigue, Anxiety, Depression, Sleep, and Ability to Participate Provide Virtually Identical Information
8:30AM-10:30AM
Abstract Number: 0906
Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 0767
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
8:30AM-10:30AM
Abstract Number: 0551
Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0923
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
8:30AM-10:30AM
Abstract Number: 0705
Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells
8:30AM-10:30AM
Abstract Number: 0840
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
8:30AM-10:30AM
Abstract Number: 0531
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
8:30AM-10:30AM
Abstract Number: 0791
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
8:30AM-10:30AM
Abstract Number: 0898
MRI Vertebral Corner Inflammation and Fat Deposition Are Associated with Whole Spine Low Dose CT Detected Syndesmophytes: A Multilevel Analysis
8:30AM-10:30AM
Abstract Number: 0883
Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study
8:30AM-10:30AM
Abstract Number: 0849
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health
8:30AM-10:30AM
Abstract Number: 0706
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0722
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
8:30AM-10:30AM
Abstract Number: 0541
N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0566
Natural Language Processing of Electronic Health Record Notes Captures Forced Vital Capacity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: PP03
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 0939
Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience
8:30AM-10:30AM
Abstract Number: 0543
Novel Insights into Systemic Sclerosis Using a Sensitive Computational Method to Analyze Whole-genome Bisulfite Sequencing Data
8:30AM-10:30AM
Abstract Number: 0583
Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing
8:30AM-10:30AM
Abstract Number: 0649
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
8:30AM-10:30AM
Abstract Number: 0758
Outcome Reporting in Self-management Interventions for Inflammatory Arthritis Trials: A Systematic Review of Outcome Measures Covering Self-management Domains
8:30AM-10:30AM
Abstract Number: 0743
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
8:30AM-10:30AM
Abstract Number: 0718
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0555
Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data
8:30AM-10:30AM
Abstract Number: 0629
Patient and Physician Satisfaction with Telemedicine Utilization for Delivery of Care in Patients with SLE – A Single Centre Experience
8:30AM-10:30AM
Abstract Number: 0814
Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
8:30AM-10:30AM
Abstract Number: 0668
Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence
8:30AM-10:30AM
Abstract Number: 0753
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 0745
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
8:30AM-10:30AM
Abstract Number: 0764
Patients with Juvenile Systemic Sclerosis Have a Distinct Pattern of Organ Involvement: Results from the Juvenile Systemic Sclerosis Inception Cohort
8:30AM-10:30AM
Abstract Number: 0710
Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease
8:30AM-10:30AM
Abstract Number: 0772
Pediatric Craniofacial Scleroderma: Assessing Handheld 3D Stereophotogrammetric Imaging Feasibility and Reliability
8:30AM-10:30AM
Abstract Number: 0512
Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
8:30AM-10:30AM
Abstract Number: 0665
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
8:30AM-10:30AM
Abstract Number: 0702
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
8:30AM-10:30AM
Abstract Number: 0748
Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
8:30AM-10:30AM
Abstract Number: 0841
Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry
8:30AM-10:30AM
Abstract Number: 0810
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0823
Pharmacokinetic and Pharmacodynamic Evaluation of a Proposed Biosimilar MSB11456 versus Both the US-licensed and EU-approved Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-dose Trial in Healthy Adults
8:30AM-10:30AM
Abstract Number: 0824
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
8:30AM-10:30AM
Abstract Number: 0618
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 0777
Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0768
Poverty and Length of Stay in Children Hospitalized with Pediatric Systemic Lupus Erythematosus: An Analysis of the 2016 Kids’ Inpatient Database
8:30AM-10:30AM
Abstract Number: 0518
Predicted Expression of Genes Involved in the Thiopurine Metabolic Pathway Is Associated with Azathioprine Discontinuation Due to Bone Marrow Toxicity
8:30AM-10:30AM
Abstract Number: 0579
Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent
8:30AM-10:30AM
Abstract Number: 0926
Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis
8:30AM-10:30AM
Abstract Number: 0585
Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0779
Predictors of Mortality in a Series of 1528 Brazilian Childhood-onset Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 0683
Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
8:30AM-10:30AM
Abstract Number: 0838
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
8:30AM-10:30AM
Abstract Number: 0574
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
8:30AM-10:30AM
Abstract Number: 0642
Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics
8:30AM-10:30AM
Abstract Number: 0862
Prevalence and Risk Factors for Herpes Zoster Reactivation in 1542 Patients with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 0843
Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
8:30AM-10:30AM
Abstract Number: 0734
Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making
8:30AM-10:30AM
Abstract Number: 0677
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
8:30AM-10:30AM
Abstract Number: 0666
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
8:30AM-10:30AM
Abstract Number: 0631
Provider Assessment of Telehealth Utility During COVID-19
8:30AM-10:30AM
Abstract Number: 0846
Psychometric Evaluation and Measurement Invariance of English and French Versions of the UCLA Loneliness Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
8:30AM-10:30AM
Abstract Number: 0797
Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0891
Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire
8:30AM-10:30AM
Abstract Number: 0616
Race and Socioeconomic Status and COVID-19 Outcomes in Patients with Rheumatic Diseases: Findings from a Tertiary Care Center in the Deep South
8:30AM-10:30AM
Abstract Number: 0771
Race, Ethnicity and Patient-Reported Outcomes in Childhood-Onset Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0619
Racial and Ethnic Disparities in Pregnancy Outcomes Among Women with Rheumatic Diseases: A Systematic Literature Review and Quantitative Analysis
8:30AM-10:30AM
Abstract Number: 0601
Racial Differences in Medication Beliefs Among SLE Patients
8:30AM-10:30AM
Abstract Number: 0596
Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs
8:30AM-10:30AM
Abstract Number: 0613
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
8:30AM-10:30AM
Abstract Number: 0907
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
8:30AM-10:30AM
Abstract Number: 0548
Rapamycin Blocks the Profibrotic Effects of Fli1 Downregulation in Scleroderma Myeloid Cells
8:30AM-10:30AM
Abstract Number: 0586
Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study
8:30AM-10:30AM
Abstract Number: 0788
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0850
Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0799
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
8:30AM-10:30AM
Abstract Number: 0792
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
8:30AM-10:30AM
Abstract Number: 0875
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
8:30AM-10:30AM
Abstract Number: 0769
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
8:30AM-10:30AM
Abstract Number: 0914
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
8:30AM-10:30AM
Abstract Number: 0554
Reverse Signaling Through PD-L1 Plays a Central Role in Extracellular Matrix Protein Secretion from Cutaneous Myofibroblasts in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0803
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
8:30AM-10:30AM
Abstract Number: 0581
Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data
8:30AM-10:30AM
Abstract Number: 0740
Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
8:30AM-10:30AM
Abstract Number: 0612
Rheumatology Care for the Underserved in Central Texas
8:30AM-10:30AM
Abstract Number: 0527
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
8:30AM-10:30AM
Abstract Number: 0831
Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
8:30AM-10:30AM
Abstract Number: 0695
Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
8:30AM-10:30AM
Abstract Number: 0730
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
8:30AM-10:30AM
Abstract Number: 0755
Satisfaction with the Process versus Outcome of Care in Total Hip and Knee Arthroplasty
8:30AM-10:30AM
Abstract Number: 0903
Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?
8:30AM-10:30AM
Abstract Number: 0892
Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0509
Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
8:30AM-10:30AM
Abstract Number: 0932
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
8:30AM-10:30AM
Abstract Number: 0691
Serum Cytokine Profiles of Patients with Adult Idiopathic Inflammatory Myopathy
8:30AM-10:30AM
Abstract Number: 0874
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
8:30AM-10:30AM
Abstract Number: 0863
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
8:30AM-10:30AM
Abstract Number: 0662
Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
8:30AM-10:30AM
Abstract Number: 0614
Sex and Race Based Utilization of Healthcare for Ocular Inflammation and Infection: Comparing the Results from the Medicare and the IRIS Data
8:30AM-10:30AM
Abstract Number: 0597
Sex Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
8:30AM-10:30AM
Abstract Number: PP08
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
8:30AM-10:30AM
Abstract Number: 0545
SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
8:30AM-10:30AM
Abstract Number: 0723
Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
8:30AM-10:30AM
Abstract Number: 0885
SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
8:30AM-10:30AM
Abstract Number: 0830
Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 0615
Socioeconomic Characteristics Associated with Electronic Health Care Utilization in an Urban Rheumatology Clinic During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 0513
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
8:30AM-10:30AM
Abstract Number: 0688
Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis
8:30AM-10:30AM
Abstract Number: 0525
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
8:30AM-10:30AM
Abstract Number: 0538
Strengthening Nuclear Envelope Ameliorates UVB-triggered Skin Inflammation and Kidney Damage in Lupus Mice
8:30AM-10:30AM
Abstract Number: 0711
Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 0837
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
8:30AM-10:30AM
Abstract Number: 0933
Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?
8:30AM-10:30AM
Abstract Number: 0844
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
8:30AM-10:30AM
Abstract Number: 0896
Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination
8:30AM-10:30AM
Abstract Number: 0861
Systemic Lupus Erythematosus, a Pilot Study of a New Disease Activity Score
8:30AM-10:30AM
Abstract Number: 0643
Tailored BP Connect Protocol with Implementation Support for Rheumatology Clinic Staff Exceeds Non-tailored Protocol at Improving Primary Care Referrals for Blood Pressure Follow-up
8:30AM-10:30AM
Abstract Number: 0829
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
8:30AM-10:30AM
Abstract Number: 0929
Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
8:30AM-10:30AM
Abstract Number: 0544
Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
8:30AM-10:30AM
Abstract Number: 0559
Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 0630
Telemedicine in Rheumatology Care: A Systematic Review
8:30AM-10:30AM
Abstract Number: 0871
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0910
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
8:30AM-10:30AM
Abstract Number: 0557
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
8:30AM-10:30AM
Abstract Number: 0594
The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
8:30AM-10:30AM
Abstract Number: 0720
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
8:30AM-10:30AM
Abstract Number: 0537
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
8:30AM-10:30AM
Abstract Number: 0536
The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice
8:30AM-10:30AM
Abstract Number: 0515
The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts
8:30AM-10:30AM
Abstract Number: 0673
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
8:30AM-10:30AM
Abstract Number: 0798
The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)
8:30AM-10:30AM
Abstract Number: 0809
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0508
The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation
8:30AM-10:30AM
Abstract Number: 0774
The Impact of Patient/Provider Discordance on Changes on Mood and Behavior in Adolescents with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0571
The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
8:30AM-10:30AM
Abstract Number: 0759
The Patient as Assessor of Disease Status: A Graphical Evaluation of Relations Between Patient-Reported Outcomes in Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0760
The Performance of RA Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis-Associated Interstitial Lung Disease in a Prospective Trial Using Pirfenidone in RA ILD (TRAIL1)
8:30AM-10:30AM
Abstract Number: 0900
The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
8:30AM-10:30AM
Abstract Number: 0820
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0519
The Relationship of Genetics and Clinically Suspect Arthralgia in RA Development Assessed Using HC, CSA and RA Patients
8:30AM-10:30AM
Abstract Number: 0558
The Systemic Sclerosis (SSc) Risk Gene A20 (TNFAIP3) and Its Repressor DREAM Determine Susceptibility to Fibrosis
8:30AM-10:30AM
Abstract Number: 0591
The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0738
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0535
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
8:30AM-10:30AM
Abstract Number: 0645
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
8:30AM-10:30AM
Abstract Number: 0721
Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis
8:30AM-10:30AM
Abstract Number: 0641
Title: EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Updated Results of Quit Connect Dissemination
8:30AM-10:30AM
Abstract Number: 0732
Topical Rofecoxib for OA of the Knee
8:30AM-10:30AM
Abstract Number: 0727
Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis
8:30AM-10:30AM
Abstract Number: 0517
TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice
8:30AM-10:30AM
Abstract Number: 0893
Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years
8:30AM-10:30AM
Abstract Number: 0526
Transcriptional Factor Profiling Denotes Specific Synovial Macrophage Heterogeneity
8:30AM-10:30AM
Abstract Number: 0523
Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
8:30AM-10:30AM
Abstract Number: 0783
Transmission Disequilibrium Testing Meets Next Generation Sequencing: Applying TDT to Whole Genome Data in Childhood-Onset Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0550
Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension
8:30AM-10:30AM
Abstract Number: 0795
Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0511
Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B
8:30AM-10:30AM
Abstract Number: 0747
Understanding Heterogeneity in Patients’ Conceptualization of Treatment for Rheumatoid Arthritis: A Cluster Analysis
8:30AM-10:30AM
Abstract Number: 0659
Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?
8:30AM-10:30AM
Abstract Number: PP01
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
8:30AM-10:30AM
Abstract Number: 0790
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
8:30AM-10:30AM
Abstract Number: 0549
Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells
8:30AM-10:30AM
Abstract Number: 0675
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
8:30AM-10:30AM
Abstract Number: 0701
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
8:30AM-10:30AM
Abstract Number: 0602
Use of a Popular Opinion Leader Model to Disseminate Information Virtually About Clinical Trial Enrollment to People of Color with Lupus
8:30AM-10:30AM
Abstract Number: 0784
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
8:30AM-10:30AM
Abstract Number: 0650
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 0811
Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0563
Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 0624
Validation of a Self-reported Measure of Extent and Reasons for Nonadherence in SLE
8:30AM-10:30AM
Abstract Number: 0804
Validation of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis (RA) in a Nursing-led Triage Clinic
8:30AM-10:30AM
Abstract Number: 0796
Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study
8:30AM-10:30AM
Abstract Number: 0756
Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis
8:30AM-10:30AM
Abstract Number: 0607
Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review
8:30AM-10:30AM
Abstract Number: 0762
Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform
8:30AM-10:30AM
Abstract Number: 0633
Value of the Routine Assessment of Patient Index Data 3 (RAPID3) as a Disease Activity Measure in Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 0539
Vgll3-transgenic Autoimmune Mice Display Features of Cutaneous Fibrosis
8:30AM-10:30AM
Abstract Number: 0735
Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
8:30AM-10:30AM
Abstract Number: 0763
What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset
8:30AM-10:30AM
Abstract Number: 0842
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
8:30AM-10:30AM
Abstract Number: 0664
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
8:30AM-10:30AM
Abstract Number: 0927
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 0575
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
9:00AM-9:15AM
Abstract Number: 0944
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
9:00AM-9:15AM
Abstract Number: 0948
Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)
9:00AM-9:15AM
Abstract Number: 0952
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
9:00AM-9:15AM
Abstract Number: 0940
Overactivation of the Kinase IKK2 Causes a Hand Osteoarthritis-Like Phenotype in Mice
9:15AM-9:30AM
Abstract Number: 0945
A Single-cell Atlas of Human Synovial Endothelial Cells in Inflammatory Arthritis
9:15AM-9:30AM
Abstract Number: 0953
An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
9:15AM-9:30AM
Abstract Number: 0941
Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA
9:15AM-9:30AM
Abstract Number: 0949
Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions
9:30AM-9:45AM
Abstract Number: 0946
Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis
9:30AM-9:45AM
Abstract Number: 0950
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa
9:30AM-9:45AM
Abstract Number: 0954
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
9:30AM-9:45AM
Abstract Number: 0942
Transcriptional Regulation of Synovial Macrophages in the Aging Joint
9:45AM-10:00AM
Abstract Number: 0951
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
9:45AM-10:00AM
Abstract Number: 0947
Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint
9:45AM-10:00AM
Abstract Number: 0943
Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis
9:45AM-10:00AM
Abstract Number: 0955
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
10:30AM-10:45AM
Abstract Number: 0962
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
10:30AM-10:45AM
Abstract Number: 0966
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
10:30AM-10:45AM
Abstract Number: 0956
Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition
10:45AM-11:00AM
Abstract Number: 0967
Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy
10:45AM-11:00AM
Abstract Number: 0963
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
10:45AM-11:00AM
Abstract Number: 0957
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
11:00AM-11:15AM
Abstract Number: 0968
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
11:00AM-11:15AM
Abstract Number: 0958
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
11:00AM-11:15AM
Abstract Number: 0964
Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
11:15AM-11:30AM
Abstract Number: 0965
Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
11:15AM-11:30AM
Abstract Number: 0959
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
11:15AM-11:30AM
Abstract Number: 0969
Loss of Balance Between Protective and Pro-inflammatory Synovial Tissue T Cell Polyfunctionality Predates Clinical Onset of Rheumatoid Arthritis
11:30AM-11:45AM
Abstract Number: 0960
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
11:45AM-12:00PM
Abstract Number: 0961
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
2:00PM-2:15PM
Abstract Number: 0970
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
2:00PM-2:15PM
Abstract Number: 0980
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
2:00PM-2:15PM
Abstract Number: 0974
Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
2:15PM-2:30PM
Abstract Number: 0981
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
2:15PM-2:30PM
Abstract Number: 0975
Data-driven MRI Definitions for Active and Structural Sacroiliac Joint Lesions in Juvenile Spondyloarthritis Typical of Axial Disease
2:15PM-2:30PM
Abstract Number: 0971
Longitudinal CyTOF Immunophenotyping Reveals Distinct Patterns of T cell-B Cell Dysregulation in SLE
2:30PM-2:45PM
Abstract Number: 0982
B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
2:30PM-2:45PM
Abstract Number: 0976
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
2:30PM-2:45PM
Abstract Number: 0972
Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis
2:45PM-3:00PM
Abstract Number: 0983
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
2:45PM-3:00PM
Abstract Number: 0977
Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
2:45PM-3:00PM
Abstract Number: 0973
Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
3:00PM-3:15PM
Abstract Number: 0978
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
3:15PM-3:30PM
Abstract Number: 0979
Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
3:30PM-3:45PM
Abstract Number: PP10
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
3:30PM-3:45PM
Abstract Number: 0984
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
3:45PM-4:00PM
Abstract Number: PP11
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
3:45PM-4:00PM
Abstract Number: 0985
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
4:00PM-4:15PM
Abstract Number: PP12
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
4:00PM-4:15PM
Abstract Number: 0986
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
4:00PM-4:15PM
Abstract Number: 0988
Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score
4:15PM-4:30PM
Abstract Number: PP13
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
4:15PM-4:30PM
Abstract Number: 0989
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
4:15PM-4:30PM
Abstract Number: 0987
Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
4:30PM-4:45PM
Abstract Number: 0990
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
4:45PM-5:00PM
Abstract Number: 0991
Does Diet Affect Gout Risk Differently Among Genetically Predisposed Women?: Prospective Female Cohort Study Findings over 34 Years
8:30AM-10:30AM
Abstract Number: 1123
“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
8:30AM-10:30AM
Abstract Number: 1165
“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
8:30AM-10:30AM
Abstract Number: 1273
A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature
8:30AM-10:30AM
Abstract Number: 1390
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1203
A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
8:30AM-10:30AM
Abstract Number: 1374
A Deep Neural Network Classifier to Identify Inflammatory Systemic Sclerosis Patients from Histological Images
8:30AM-10:30AM
Abstract Number: 1152
A Follow-Up Evaluation of a Longstanding Telephone Peer Counseling Service for People with Systemic Lupus Erythematosus and Their Loved Ones
8:30AM-10:30AM
Abstract Number: 1384
A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1194
A Module on Large Vessel Vasculitis for Learners in Rheumatology
8:30AM-10:30AM
Abstract Number: 1255
A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
8:30AM-10:30AM
Abstract Number: 1079
A Multifaceted Approach to Increasing Enrollment and Activation of Pediatric Rheumatology Patient Portal Profiles
8:30AM-10:30AM
Abstract Number: 1223
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
8:30AM-10:30AM
Abstract Number: 1185
A New Virtual Reality: Needs Assessment and Gains in Current Trainees Experience with a Novel Video-Based Post Rheumatology Rotation Intervention
8:30AM-10:30AM
Abstract Number: 1164
A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
8:30AM-10:30AM
Abstract Number: 1207
A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1250
Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue
8:30AM-10:30AM
Abstract Number: 1253
Acupuncture in Rheumatoid Arthritis Activity
8:30AM-10:30AM
Abstract Number: 1369
Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial
8:30AM-10:30AM
Abstract Number: 1248
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
8:30AM-10:30AM
Abstract Number: 1398
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
8:30AM-10:30AM
Abstract Number: 1393
All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
8:30AM-10:30AM
Abstract Number: 1092
Altered Metabolic Pathways in Synovial Fibroblasts of Individuals at Risk of Developing Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1012
Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
8:30AM-10:30AM
Abstract Number: 1400
Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study
8:30AM-10:30AM
Abstract Number: 1068
Analysis of Tweets Containing Information Related to Rheumatological Diseases on Twitter
8:30AM-10:30AM
Abstract Number: 1177
Assessing Resident Needs and Faculty Perceptions for Rheumatology Curriculum Development
8:30AM-10:30AM
Abstract Number: 1138
Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States
8:30AM-10:30AM
Abstract Number: 1392
Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica
8:30AM-10:30AM
Abstract Number: 1377
Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies
8:30AM-10:30AM
Abstract Number: 1328
Assessment of Microvascular Involvement in Psoriatic Arthritis by Nailfold Capillaroscopy
8:30AM-10:30AM
Abstract Number: 1016
Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice
8:30AM-10:30AM
Abstract Number: 1132
Association Between Serum Selenium Level and the Prevalence of Osteoarthritis: Data from the Xiangya Osteoarthritis Study
8:30AM-10:30AM
Abstract Number: 1121
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
8:30AM-10:30AM
Abstract Number: 1287
Association of Limited Health Literacy with Patient-Provider Communication in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1221
Association of Neutrophil Lymphocyte and Platelet Lymphocyte Ratios with Joint Inflammation in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1259
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
8:30AM-10:30AM
Abstract Number: 1303
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
8:30AM-10:30AM
Abstract Number: 1367
Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1101
Atypical Pulmonary Radiographic Findings May Help Identify Patients with Usual Interstitial Pneumonia and Autoimmune Features
8:30AM-10:30AM
Abstract Number: 1364
Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
8:30AM-10:30AM
Abstract Number: 1396
Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
8:30AM-10:30AM
Abstract Number: 1168
Barriers to Effectiveness of Non-surgical Treatments for Knee Osteoarthritis in a Diverse Racial/Ethnic Population: A Nominal Group Qualitative Study
8:30AM-10:30AM
Abstract Number: 1225
Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
8:30AM-10:30AM
Abstract Number: 1295
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
8:30AM-10:30AM
Abstract Number: 1175
Best Practice Guidelines for Telehealth in Rheumatology: An Initiative by the Arab League of Associations for Rheumatology
8:30AM-10:30AM
Abstract Number: 1180
Better Websites, Better Match: Assessing Quality of Rheumatology Fellowship Websites
8:30AM-10:30AM
Abstract Number: 1338
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
8:30AM-10:30AM
Abstract Number: 1240
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
8:30AM-10:30AM
Abstract Number: 1322
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
8:30AM-10:30AM
Abstract Number: 1173
Bringing Reproductive Health Guidelines into Fellowship Training: A National Survey of Adult and Pediatric Rheumatology Fellows and Program Directors to Assess Educational Need and Inform Curriculum Development
8:30AM-10:30AM
Abstract Number: 1093
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
8:30AM-10:30AM
Abstract Number: 1319
Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1032
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
8:30AM-10:30AM
Abstract Number: 1005
CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
8:30AM-10:30AM
Abstract Number: 1368
Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
8:30AM-10:30AM
Abstract Number: 1099
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
8:30AM-10:30AM
Abstract Number: 1245
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
8:30AM-10:30AM
Abstract Number: 1407
Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles
8:30AM-10:30AM
Abstract Number: 1056
Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study
8:30AM-10:30AM
Abstract Number: 1272
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
8:30AM-10:30AM
Abstract Number: 1381
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1019
Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 0997
Citrullinated Vimentin Induces Epigenetic Memory of the Innate Immune System
8:30AM-10:30AM
Abstract Number: 1282
Classification of Disease Activity and Damage in Cutaneous Lupus
8:30AM-10:30AM
Abstract Number: 1107
Clinical and Genetic Features of Chinese Adult Patients with Chronic Non-bacterial Osteomyelitis: A Single Center Report
8:30AM-10:30AM
Abstract Number: 1031
Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
8:30AM-10:30AM
Abstract Number: 1306
Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients
8:30AM-10:30AM
Abstract Number: 1357
Clinical and Molecular Profiles Determining Cardiovascular Risk in Psoriatic Arthritis: Specific Response to Apremilast and Methotrexate
8:30AM-10:30AM
Abstract Number: 1089
Clinical Associations of Anti-Ro52 Antibodies in Patients with Systemic Autoimmune Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1298
Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
8:30AM-10:30AM
Abstract Number: 1310
Clinical Characteristics of Patients with SpA and Concomitant IBD: Results from the ASAS PerSpA Study
8:30AM-10:30AM
Abstract Number: 1409
Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
8:30AM-10:30AM
Abstract Number: 1278
Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
8:30AM-10:30AM
Abstract Number: 1227
Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
8:30AM-10:30AM
Abstract Number: 1402
Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy
8:30AM-10:30AM
Abstract Number: 1358
Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study
8:30AM-10:30AM
Abstract Number: 1076
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
8:30AM-10:30AM
Abstract Number: 1102
Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
8:30AM-10:30AM
Abstract Number: 1346
Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
8:30AM-10:30AM
Abstract Number: 1061
Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System
8:30AM-10:30AM
Abstract Number: 1109
Comparison of Diagnostic Criteria in Behçet’s Disease and Sensitivity in Diagnosing Severe Manifestations
8:30AM-10:30AM
Abstract Number: 1241
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
8:30AM-10:30AM
Abstract Number: 1370
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
8:30AM-10:30AM
Abstract Number: 1208
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
8:30AM-10:30AM
Abstract Number: 1045
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 1231
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
8:30AM-10:30AM
Abstract Number: 1090
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
8:30AM-10:30AM
Abstract Number: 1129
Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
8:30AM-10:30AM
Abstract Number: 1085
COVID 19 Infection in Patients with Rheumatic Immune-mediated Diseases in a Single University Hospital: Matched Case-control Study
8:30AM-10:30AM
Abstract Number: 1084
COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry
8:30AM-10:30AM
Abstract Number: 1030
Critical Illness in Modern Rheumatology: Analysis of Admissions to Australian and New Zealand ICUs
8:30AM-10:30AM
Abstract Number: 1110
Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience
8:30AM-10:30AM
Abstract Number: 1096
CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
8:30AM-10:30AM
Abstract Number: 1204
CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1311
De Novo Psoriasis Can Be Reported at Any Timepoint in Early Axial Spondyloarthritis: An Analysis of 6 Years of Follow-up of the DESIR Cohort
8:30AM-10:30AM
Abstract Number: 1411
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
8:30AM-10:30AM
Abstract Number: 1179
Determining Faculty vs. Fellow Preferences for ROSCE Milestone Assessments; Is It Time for a Change in Needs Assessment?
8:30AM-10:30AM
Abstract Number: 1352
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
8:30AM-10:30AM
Abstract Number: 1419
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
8:30AM-10:30AM
Abstract Number: 1215
Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
8:30AM-10:30AM
Abstract Number: 1239
Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1354
Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
8:30AM-10:30AM
Abstract Number: 1275
Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
8:30AM-10:30AM
Abstract Number: 1252
Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies
8:30AM-10:30AM
Abstract Number: 1217
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
8:30AM-10:30AM
Abstract Number: 1105
Discovering Variants in Suspected Monogenic Systemic Inflammatory Disease: An Adult Case Series
8:30AM-10:30AM
Abstract Number: 1103
Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study
8:30AM-10:30AM
Abstract Number: 1116
Disease Characteristics of Steroid-Induced Spinal Epidural Lipomatosis: A Systematic Review
8:30AM-10:30AM
Abstract Number: 1270
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1041
Do Cancer Risks Increased in the Five Major Autoimmune Diseases? A Large Cohort Study in China
8:30AM-10:30AM
Abstract Number: 1229
Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
8:30AM-10:30AM
Abstract Number: 1098
Does Cancer Masquerade as Sarcoidosis?
8:30AM-10:30AM
Abstract Number: 1222
Drug Response Is Associated with Changes in Specific MicroRNAs in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1416
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
8:30AM-10:30AM
Abstract Number: 1301
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
8:30AM-10:30AM
Abstract Number: 1330
Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
8:30AM-10:30AM
Abstract Number: 1300
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1080
Effect of Triage by a Rheumatologist in a Primary Care Setting
8:30AM-10:30AM
Abstract Number: 1077
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
8:30AM-10:30AM
Abstract Number: 1120
Effectiveness of Stretching and Bracing for the Treatment of Osteoarthritis-associated Joint Contractures Prior to Joint Replacement: A Systematic Review
8:30AM-10:30AM
Abstract Number: 1405
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
8:30AM-10:30AM
Abstract Number: 1412
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
8:30AM-10:30AM
Abstract Number: 1356
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1336
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1149
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 1183
Efficacy of Rapid Transition of a Musculoskeletal/Rheumatology/Dermatology Course to Online Learning During COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1014
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
8:30AM-10:30AM
Abstract Number: 1020
Enhancing Endothelial Cell Barrier Function via Sphingosine -1 Phosphate Receptor 1 (S1PR1) – a Novel Treatment for Experimental Arthritis
8:30AM-10:30AM
Abstract Number: 1050
Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain
8:30AM-10:30AM
Abstract Number: 1326
Epidemiology of Comorbidities in an Incident Psoriasis Cohort: A Population-Based Study
8:30AM-10:30AM
Abstract Number: 1027
Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients
8:30AM-10:30AM
Abstract Number: 1170
Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
8:30AM-10:30AM
Abstract Number: 1048
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
8:30AM-10:30AM
Abstract Number: 1066
Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
8:30AM-10:30AM
Abstract Number: 1160
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
8:30AM-10:30AM
Abstract Number: 1211
Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1029
Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
8:30AM-10:30AM
Abstract Number: 1216
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1214
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1124
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
8:30AM-10:30AM
Abstract Number: 1001
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1009
Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
8:30AM-10:30AM
Abstract Number: 1176
Experience from TheMednet: Online Rheumatology Physician Social Network
8:30AM-10:30AM
Abstract Number: 1151
Experiences and Finding Meaning Among Latin Americans Living with Lupus: Learning from Social Media Narratives by Patients and Their Social Network
8:30AM-10:30AM
Abstract Number: 1067
Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study
8:30AM-10:30AM
Abstract Number: 1070
Experiences of Wearable Technology by Persons with Knee Osteoarthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Lens
8:30AM-10:30AM
Abstract Number: 1071
Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
8:30AM-10:30AM
Abstract Number: 1162
Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
8:30AM-10:30AM
Abstract Number: 1047
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
8:30AM-10:30AM
Abstract Number: 1094
Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
8:30AM-10:30AM
Abstract Number: 1297
Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
8:30AM-10:30AM
Abstract Number: 1141
Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre
8:30AM-10:30AM
Abstract Number: 1256
Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1026
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
8:30AM-10:30AM
Abstract Number: 1260
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1052
Female Reproductive Factors and Risk of Joint Replacement Arthroplasty of the Knee and Hip Due to Osteoarthritis in Postmenopausal Women: A Nationwide Cohort Study of 1.36 Million Women
8:30AM-10:30AM
Abstract Number: 1288
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
8:30AM-10:30AM
Abstract Number: 1262
Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1142
For Vulnerable Population Treated at a Community Health Center (CHC), Primary Care Physician (PCP) Turnover Should Be Included in Social Determinants of Health (SDH) on Non-completing Osteoporosis Treatment
8:30AM-10:30AM
Abstract Number: 1139
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
8:30AM-10:30AM
Abstract Number: 1140
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
8:30AM-10:30AM
Abstract Number: 1267
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
8:30AM-10:30AM
Abstract Number: 1210
Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1097
Gastrointestinal Malignancies in Sarcoidosis: A Nationwide Analysis
8:30AM-10:30AM
Abstract Number: 1280
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1403
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
8:30AM-10:30AM
Abstract Number: 1331
Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
8:30AM-10:30AM
Abstract Number: 1329
Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
8:30AM-10:30AM
Abstract Number: 1333
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
8:30AM-10:30AM
Abstract Number: 1335
Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1343
Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
8:30AM-10:30AM
Abstract Number: 1271
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
8:30AM-10:30AM
Abstract Number: 1039
Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
8:30AM-10:30AM
Abstract Number: 1388
Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus
8:30AM-10:30AM
Abstract Number: 1308
Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls
8:30AM-10:30AM
Abstract Number: 1334
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
8:30AM-10:30AM
Abstract Number: 1055
How to Optimize E-Recruitment Strategies: Lessons Learned from over 3000 Participants in an International Arab Online Study
8:30AM-10:30AM
Abstract Number: 1363
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA
8:30AM-10:30AM
Abstract Number: 1220
Identification of Underlying Disease Domains by Longitudinal Latent Factor Analysis for Secukinumab Treated Patients in Psoriatic Arthritis and Rheumatoid Arthritis Trials
8:30AM-10:30AM
Abstract Number: 1344
Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
8:30AM-10:30AM
Abstract Number: 1279
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
8:30AM-10:30AM
Abstract Number: 1327
Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules
8:30AM-10:30AM
Abstract Number: 1361
Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
8:30AM-10:30AM
Abstract Number: 1057
Impact of Osteoarthritis in Younger Adults
8:30AM-10:30AM
Abstract Number: 1230
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
8:30AM-10:30AM
Abstract Number: 1309
Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS
8:30AM-10:30AM
Abstract Number: 1156
Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
8:30AM-10:30AM
Abstract Number: 1317
Impairment of Memory in Axial Spondyloarthritis?
8:30AM-10:30AM
Abstract Number: 1178
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
8:30AM-10:30AM
Abstract Number: 1095
Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
8:30AM-10:30AM
Abstract Number: 1375
Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1257
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1159
Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions
8:30AM-10:30AM
Abstract Number: 1081
Improving Rheumatology Resource Utilization and Access to Specialty Care for Patients with Early Inflammatory Arthritis Through Enhanced Triage
8:30AM-10:30AM
Abstract Number: 1073
In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1249
In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
8:30AM-10:30AM
Abstract Number: 1406
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
8:30AM-10:30AM
Abstract Number: 1022
Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
8:30AM-10:30AM
Abstract Number: 1304
Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 0998
Increasing Age Impairs the Metabolic Adaptation of Human Neutrophils to Glucose Deprivation
8:30AM-10:30AM
Abstract Number: 0992
Inflammatory Arthritis in HIV-Infected Humanized Mice
8:30AM-10:30AM
Abstract Number: 0995
Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
8:30AM-10:30AM
Abstract Number: 1128
Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
8:30AM-10:30AM
Abstract Number: 1131
Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance
8:30AM-10:30AM
Abstract Number: 1318
Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
8:30AM-10:30AM
Abstract Number: 1191
Introduction of a Joint Injection and Ultrasound Workshop for Internal Medicine Trainees
8:30AM-10:30AM
Abstract Number: 1187
Is Your Program Website Optimized for Recruitment? An Evaluation of Rheumatology Fellowship Program Websites
8:30AM-10:30AM
Abstract Number: 1347
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
8:30AM-10:30AM
Abstract Number: 1341
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1018
Joint-Draining Popliteal Lymphatic Vessels Exhibit Lymphatic Muscle Cell Dysfunction in TNF-Tg Mice with Inflammatory Arthritis
8:30AM-10:30AM
Abstract Number: 1349
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
8:30AM-10:30AM
Abstract Number: 1028
Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative
8:30AM-10:30AM
Abstract Number: 1086
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
8:30AM-10:30AM
Abstract Number: 1345
Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study
8:30AM-10:30AM
Abstract Number: 1337
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
8:30AM-10:30AM
Abstract Number: 1281
Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures
8:30AM-10:30AM
Abstract Number: 1299
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
8:30AM-10:30AM
Abstract Number: 1224
Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab
8:30AM-10:30AM
Abstract Number: 1342
Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year
8:30AM-10:30AM
Abstract Number: 1238
Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1404
Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study
8:30AM-10:30AM
Abstract Number: 1006
MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)
8:30AM-10:30AM
Abstract Number: 1219
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 1417
Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors
8:30AM-10:30AM
Abstract Number: 1387
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1285
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
8:30AM-10:30AM
Abstract Number: 1004
Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1166
Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe
8:30AM-10:30AM
Abstract Number: 1258
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
8:30AM-10:30AM
Abstract Number: 1386
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
8:30AM-10:30AM
Abstract Number: 1024
Medical Care Seeking Is Frequent and Associated with Overuse of Low-Value Care for Low Back Pain in Portugal: Results from a Nationwide Population-Based Study
8:30AM-10:30AM
Abstract Number: 1054
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
8:30AM-10:30AM
Abstract Number: 1244
Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study
8:30AM-10:30AM
Abstract Number: 1000
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
8:30AM-10:30AM
Abstract Number: 1040
Monoclonal Gammopathy in Autoimmune Diseases: Analysis and Follow-up of 160 Cases in a Tertiary Center in China
8:30AM-10:30AM
Abstract Number: 1108
More Frequent, Earlier Hip Involvement and Poor Outcome in Spondyloarthritis Associated with Familial Mediterranean Fever
8:30AM-10:30AM
Abstract Number: 1196
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
8:30AM-10:30AM
Abstract Number: 1296
Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study
8:30AM-10:30AM
Abstract Number: 1049
Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study
8:30AM-10:30AM
Abstract Number: 1042
Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study
8:30AM-10:30AM
Abstract Number: 1193
Musculoskeletal Ultrasound Instruction in US and Canadian Pediatric Rheumatology Fellowship Programs
8:30AM-10:30AM
Abstract Number: 1171
Needs Assessment of a Rheumatology Curriculum for Internal Medicine Residents
8:30AM-10:30AM
Abstract Number: 1002
Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis
8:30AM-10:30AM
Abstract Number: 1195
NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences
8:30AM-10:30AM
Abstract Number: 1362
No Change in Bone Marrow Edema of the Sacroiliac Joints and Spine After High Intensity Interval Training in PsA
8:30AM-10:30AM
Abstract Number: 1320
Obesity and Its Associations with Clinical Manifestations and Disease Burden of Patients with Spondyloarthritis: An Ancillary Study from the ASAS-perSpA Project
8:30AM-10:30AM
Abstract Number: 1117
Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center
8:30AM-10:30AM
Abstract Number: 1044
Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications
8:30AM-10:30AM
Abstract Number: 1284
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
8:30AM-10:30AM
Abstract Number: 1065
Optimizing Joint Pain EConsult Referrals in an Underserved Region of Southern California
8:30AM-10:30AM
Abstract Number: 1021
Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 1130
Osteoarthritis Patients Feel Their Tissue Remodeling
8:30AM-10:30AM
Abstract Number: 1134
Osteoarthritis Risk Is Increased in Patients with Atopic Disease
8:30AM-10:30AM
Abstract Number: 1017
Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
8:30AM-10:30AM
Abstract Number: 1135
Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
8:30AM-10:30AM
Abstract Number: 1325
Osteoporosis in Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1376
Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review
8:30AM-10:30AM
Abstract Number: 1372
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
8:30AM-10:30AM
Abstract Number: 1083
Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
8:30AM-10:30AM
Abstract Number: 1038
Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions
8:30AM-10:30AM
Abstract Number: 1385
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
8:30AM-10:30AM
Abstract Number: 1114
Pachymeningitis: The Mayo Clinic Experience
8:30AM-10:30AM
Abstract Number: 1236
Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
8:30AM-10:30AM
Abstract Number: 1192
Palliative Care for the Rheumatologist: An Educational and Patient Care Intervention
8:30AM-10:30AM
Abstract Number: 1265
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
8:30AM-10:30AM
Abstract Number: 1373
Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1104
Pathogenic UBA1 Variants in Japanese Patients with Relapsing Polychondritis
8:30AM-10:30AM
Abstract Number: 1157
Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
8:30AM-10:30AM
Abstract Number: 1277
Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms
8:30AM-10:30AM
Abstract Number: 1161
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
8:30AM-10:30AM
Abstract Number: 1169
Patient Preferences for Outcome Measures for a Pragmatic Knee Osteoarthritis (OA) Clinical Trial: Results of a Cross-Sectional Patient Survey That Included Racial/Ethnic Minorities
8:30AM-10:30AM
Abstract Number: 1418
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
8:30AM-10:30AM
Abstract Number: 1122
Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
8:30AM-10:30AM
Abstract Number: 1289
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
8:30AM-10:30AM
Abstract Number: 1163
Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
8:30AM-10:30AM
Abstract Number: 1197
Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
8:30AM-10:30AM
Abstract Number: 1213
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
8:30AM-10:30AM
Abstract Number: 1064
Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Private Rheumatology Practice: Patient Outcomes
8:30AM-10:30AM
Abstract Number: 1106
Phenotypes and Genotypes of NLRP3-AID in Chinese Adult Patients
8:30AM-10:30AM
Abstract Number: 1033
Physical Inactivity Among Adults with Specific Chronic Conditions, by Arthritis Status, 49 States and District of Columbia, Behavioral Risk Factor Surveillance System, 2019
8:30AM-10:30AM
Abstract Number: 1233
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
8:30AM-10:30AM
Abstract Number: 1182
Pilot Health Literacy Curriculum Addressing Skills and Content Knowledge for Adult and Pediatric Rheumatology Fellows
8:30AM-10:30AM
Abstract Number: 1209
Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
8:30AM-10:30AM
Abstract Number: 1247
Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1172
Podcast-Based Learning, a Valuable Tool for Learning Rheumatology
8:30AM-10:30AM
Abstract Number: 1015
Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
8:30AM-10:30AM
Abstract Number: 1268
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
8:30AM-10:30AM
Abstract Number: 1200
Predicting Progression to RA in Patients with Seropositive Arthralgia
8:30AM-10:30AM
Abstract Number: 1228
Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting
8:30AM-10:30AM
Abstract Number: 1212
Prediction of 1-Year Intravenous Abatacept Retention in Patients with RA Using Novel Machine Learning Techniques: Directionality and Importance of Predictors
8:30AM-10:30AM
Abstract Number: 1383
Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model
8:30AM-10:30AM
Abstract Number: 1314
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
8:30AM-10:30AM
Abstract Number: 1348
Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 Mg Once Daily: Pooled Analysis of Two Phase 3 Studies
8:30AM-10:30AM
Abstract Number: 1294
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
8:30AM-10:30AM
Abstract Number: 1205
Predictors of Discordance Between Patient and Physician Global Assessment in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1143
Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis
8:30AM-10:30AM
Abstract Number: 1410
Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
8:30AM-10:30AM
Abstract Number: 1276
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
8:30AM-10:30AM
Abstract Number: 1237
Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1155
Pregnancy Experiences and Unmet Needs for Women of Childbearing Age with Chronic Rheumatic Disease in China
8:30AM-10:30AM
Abstract Number: 1378
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
8:30AM-10:30AM
Abstract Number: 1148
Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases
8:30AM-10:30AM
Abstract Number: 1145
Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru
8:30AM-10:30AM
Abstract Number: 1043
Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study
8:30AM-10:30AM
Abstract Number: 1010
Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
8:30AM-10:30AM
Abstract Number: 1355
Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
8:30AM-10:30AM
Abstract Number: 1100
Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
8:30AM-10:30AM
Abstract Number: 1380
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
8:30AM-10:30AM
Abstract Number: 1266
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1023
Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network
8:30AM-10:30AM
Abstract Number: 1264
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
8:30AM-10:30AM
Abstract Number: 1034
Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study
8:30AM-10:30AM
Abstract Number: 1243
Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
8:30AM-10:30AM
Abstract Number: 1283
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
8:30AM-10:30AM
Abstract Number: 1365
Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1137
REMS Technology for the Assessment of Bone Health in a Male Population
8:30AM-10:30AM
Abstract Number: 1158
Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
8:30AM-10:30AM
Abstract Number: 1167
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
8:30AM-10:30AM
Abstract Number: 1190
Rheumatology Continuing Professional Development for Primary Care Providers: A Systematic Review
8:30AM-10:30AM
Abstract Number: 1291
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1046
Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
8:30AM-10:30AM
Abstract Number: 1136
Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts
8:30AM-10:30AM
Abstract Number: 1359
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
8:30AM-10:30AM
Abstract Number: 1391
Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial
8:30AM-10:30AM
Abstract Number: 0994
Role of SLE Associated Cytokines in Generation of Mature Neutrophils
8:30AM-10:30AM
Abstract Number: 1234
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
8:30AM-10:30AM
Abstract Number: 1078
Rural Veterans with Gout – “Rheum” for Improvement
8:30AM-10:30AM
Abstract Number: 1013
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
8:30AM-10:30AM
Abstract Number: 1074
Satisfaction with a Virtual Learning Collaborative Aimed at Implementing Treat to Target (TTT) in Rheumatoid Arthritis (RA)
8:30AM-10:30AM
Abstract Number: 1181
Self Directed Learning Among Internal Medicine Residents: Incorporating a New Teaching Module on Calcium Pyrophosphate Deposition in the Rheumatology Curriculum
8:30AM-10:30AM
Abstract Number: 1251
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1379
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1206
Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1091
Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly
8:30AM-10:30AM
Abstract Number: 1274
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
8:30AM-10:30AM
Abstract Number: 1242
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1058
Sex-Specific Associations Between Knee Synovial Fluid Biomarkers and Knee Osteoarthritis Pain
8:30AM-10:30AM
Abstract Number: 1188
Sifting Through Complexity in a Methodological Manner: Identifying Key Items in Teaching Lupus to Medical Students Through Consensus
8:30AM-10:30AM
Abstract Number: 1003
Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures
8:30AM-10:30AM
Abstract Number: 1146
Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting
8:30AM-10:30AM
Abstract Number: 1293
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
8:30AM-10:30AM
Abstract Number: 1389
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
8:30AM-10:30AM
Abstract Number: 1069
Supporting Patient-Centered Care in the Pediatric Rheumatology Setting: Patient, Family and Provider Experiences with OurNotes
8:30AM-10:30AM
Abstract Number: 1382
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1025
Survival of Patients with Idiopathic Inflammatory Myopathy in Slovenia
8:30AM-10:30AM
Abstract Number: 1350
Sustained Improvement in Physical Function, Disease Impact and Health­-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study
8:30AM-10:30AM
Abstract Number: 1371
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
8:30AM-10:30AM
Abstract Number: 1126
Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 1127
Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
8:30AM-10:30AM
Abstract Number: 1008
Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
8:30AM-10:30AM
Abstract Number: 1125
Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
8:30AM-10:30AM
Abstract Number: 1232
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1119
Systematic Review of Non-surgical Therapies for Hand Osteoarthritis
8:30AM-10:30AM
Abstract Number: 1292
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
8:30AM-10:30AM
Abstract Number: 1174
Teaching and Reproducibility of a Pediatric Musculoskeletal Ultrasound Scoring System
8:30AM-10:30AM
Abstract Number: 1062
Telemedicine Enriched Care Model to Optimize Care for Patients with Autoinflammatory Diseases
8:30AM-10:30AM
Abstract Number: 1415
Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence
8:30AM-10:30AM
Abstract Number: 1053
Temporal Trends and Geographic Variations of Premature Mortality Related to Musculoskeletal(MSK) and Connective Tissue Disorders in the United States: A 20-Year Analysis from WONDER Database
8:30AM-10:30AM
Abstract Number: 1060
Temporal Trends of Arthropathies Related Mortality in the United States and Its Regional Variations from 1999-2018
8:30AM-10:30AM
Abstract Number: 1088
The Association Between Anti-Type Ⅱ Collagen Antibodies at the Time of Diagnosis and Recurrence in Relapsing Polychondritis
8:30AM-10:30AM
Abstract Number: 1118
The Association of Hand OA with Paid an Unpaid Work Impairment and Related Costs: The Hand Osteoarthritis in Secondary Care Cohort
8:30AM-10:30AM
Abstract Number: 1059
The Association of Pain and Sleep in Relation to Depressive Symptoms Among Older Adults with Arthritis
8:30AM-10:30AM
Abstract Number: 1036
The Association of Patient Uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1315
The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1269
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
8:30AM-10:30AM
Abstract Number: 1414
The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States
8:30AM-10:30AM
Abstract Number: 1246
The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1035
The ELSA-Brasil Musculoskeletal Cohort (ELSA-Brasil MSK): Design, Implementation and Prevalence of Chronic Musculoskeletal Pain and Radiographic Knee Osteoarthritis at Baseline
8:30AM-10:30AM
Abstract Number: 1087
The Humoral Immunity of mRNA-Based SARS-CoV2 Vaccine in Autoimmune Rheumatic Disease Patients Receiving Immunomodulators
8:30AM-10:30AM
Abstract Number: 1075
The Impact of an Integrated Care Management Program on Acute Care Use for Potentially Avoidable Conditions Among High-Risk Patients with SLE
8:30AM-10:30AM
Abstract Number: 1313
The Impact of Comorbidities on Patients with Axial Spondyloarthritis: A Cluster Analysis
8:30AM-10:30AM
Abstract Number: 1261
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1351
The Impact of Skin Involvement and Depression on Patient Acceptable Symptom State in Patients with Psoriatic Arthritis and Psoriasis: Results from a Multinational Survey
8:30AM-10:30AM
Abstract Number: 1153
The Influence of Companions on a Patient’s Decision to Transition to a Biosimilar: A Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 1186
The Kardashian Index of Rheumatology Program Directors: Comparing Scholarly Activity and Twitter Use of Rheumatology Fellowship Program Directors in the United States
8:30AM-10:30AM
Abstract Number: 0993
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
8:30AM-10:30AM
Abstract Number: 1072
The Multidisciplinary Approach with Patient Collaboration Improve the Clinical Effectiveness of the Intervention
8:30AM-10:30AM
Abstract Number: 1226
The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA
8:30AM-10:30AM
Abstract Number: 1133
The Relation of Serum Urate to Radiographic Knee Osteoarthritis in 2 Cohorts: The ELSA-Brasil MSK and the Original Cohort of the Framingham Heart Study
8:30AM-10:30AM
Abstract Number: 1082
The Rheumatology Workforce in Canada: Results of the Workforce and Wellness Survey
8:30AM-10:30AM
Abstract Number: 1254
The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
8:30AM-10:30AM
Abstract Number: 0996
The Stimulator of Interferon Genes (STING) Protects from Bone Loss Through Regulation of Tonic and Induced Type I Interferon Pathways
8:30AM-10:30AM
Abstract Number: 1366
The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?
8:30AM-10:30AM
Abstract Number: 1147
Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
8:30AM-10:30AM
Abstract Number: 1413
Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis
8:30AM-10:30AM
Abstract Number: 1112
Transient Elastography (Fibroscan) as a Non-Invasive Method for Detecting Amyloid Deposition in Transplanted Kidneys in Patients with AA Amyloidosis
8:30AM-10:30AM
Abstract Number: 1111
Transient Elastography (fibroscan); As a New Non-invasive Diagnostic Method for Detecting Hepatic Involvement of Amyloidosis
8:30AM-10:30AM
Abstract Number: 1235
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
8:30AM-10:30AM
Abstract Number: 1408
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
8:30AM-10:30AM
Abstract Number: 1397
Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
8:30AM-10:30AM
Abstract Number: 1263
Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
8:30AM-10:30AM
Abstract Number: 1339
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
8:30AM-10:30AM
Abstract Number: 1286
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
8:30AM-10:30AM
Abstract Number: 1198
Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome
8:30AM-10:30AM
Abstract Number: 1360
Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study
8:30AM-10:30AM
Abstract Number: 1199
Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development
8:30AM-10:30AM
Abstract Number: 1189
Ultrasound Online: A Novel Approach to Teaching Rheumatology Focused Musculoskeletal Ultrasonography to Resident Physicians in Training
8:30AM-10:30AM
Abstract Number: 1144
Underestimation of the Fracture Risk by the FRAX Formula in Chronic Glucocorticoid Users: A 10-year Longitudinal Validation Study
8:30AM-10:30AM
Abstract Number: 1305
Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study
8:30AM-10:30AM
Abstract Number: 1218
Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort
8:30AM-10:30AM
Abstract Number: 1340
Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
8:30AM-10:30AM
Abstract Number: 1150
Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
8:30AM-10:30AM
Abstract Number: 1063
Use of Telemedicine for Rheumatology Practice in Queensland, Australia: Experiences Before and During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1395
Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients
8:30AM-10:30AM
Abstract Number: 1401
Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
8:30AM-10:30AM
Abstract Number: 0999
UVB-irradiated Keratinocyte-derived Extracellular Vesicles Induced Proinflammatory Responses in Macrophages
8:30AM-10:30AM
Abstract Number: 1115
Uveitis and Inflammatory Bowel Disease: Study of 1449 Patients from a Single University Center
8:30AM-10:30AM
Abstract Number: 1324
Uveitis in 301 Patients with Axial Spondyloarthritis of a Single University Center: Epidemiology, Clinical Features and Biological Treatment
8:30AM-10:30AM
Abstract Number: 1323
Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center
8:30AM-10:30AM
Abstract Number: 1321
Uveitis in Patients with Psoriatic Arthritis – a Database Analysis
8:30AM-10:30AM
Abstract Number: 1307
Uveitis in Spondyloarthritis Patients. Is There Any Specific Clinical Picture?
8:30AM-10:30AM
Abstract Number: 1399
Validation of a Giant Cell Arteritis Probability Score
8:30AM-10:30AM
Abstract Number: 1290
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials
8:30AM-10:30AM
Abstract Number: 1011
Validation of Bioinformatics Pipeline to Detect NEMO-Deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) and Preliminary Clinical and Immunologic Characterization
8:30AM-10:30AM
Abstract Number: 1113
Validation of the 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease in a Latin American Cohort
8:30AM-10:30AM
Abstract Number: 1332
Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)
8:30AM-10:30AM
Abstract Number: 1051
Variance of Joint Space Width Across the Tibiofemoral Joint on Knee Radiographs: A Novel Measure of Structure and Progression
8:30AM-10:30AM
Abstract Number: 1037
Variations in Total Knee Replacement Utilization and Outcomes in USA and Canada: The Role of Geography and Socioeconomic Factors
8:30AM-10:30AM
Abstract Number: 1007
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
8:30AM-10:30AM
Abstract Number: 1394
Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States
8:30AM-10:30AM
Abstract Number: 1316
Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 1184
Voluntary Online Gout Module: Housestaff Utilization and Efficacy
8:30AM-10:30AM
Abstract Number: 1154
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
8:30AM-10:30AM
Abstract Number: 1312
What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis?
8:30AM-10:30AM
Abstract Number: 1353
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1202
Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
8:30AM-10:30AM
Abstract Number: 1302
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
8:30AM-10:30AM
Abstract Number: 1201
Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
9:00AM-9:15AM
Abstract Number: 1420
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
9:15AM-9:30AM
Abstract Number: 1421
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
9:30AM-9:45AM
Abstract Number: 1422
Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
9:45AM-10:00AM
Abstract Number: 1423
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
10:30AM-10:45AM
Abstract Number: 1430
Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19
10:30AM-10:45AM
Abstract Number: 1434
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
10:30AM-10:45AM
Abstract Number: 1424
Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study
10:45AM-11:00AM
Abstract Number: 1431
Human TLR8 Leads to Fatal Anemia Due to Ineffective Erythropoiesis in Bone Marrow Erythroblastic Islands in Murine SLE
10:45AM-11:00AM
Abstract Number: 1435
Identification of Distinct Fibroblast Populations in Systemic Sclerosis 3D Skin Tissues with Single Cell Omics
10:45AM-11:00AM
Abstract Number: 1425
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
11:00AM-11:15AM
Abstract Number: 1436
Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis
11:00AM-11:15AM
Abstract Number: 1426
Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
11:00AM-11:15AM
Abstract Number: 1432
Modulation of Auto-Inflammation with a Novel Selective Cyclic GMP-AMP Synthase (cGAS) Inhibitor in a Trex1-/- Model
11:15AM-11:30AM
Abstract Number: 1433
Endothelium-protective, Histone-neutralizing Properties of the Polyanionic Agent Defibrotide
11:15AM-11:30AM
Abstract Number: 1437
Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
11:15AM-11:30AM
Abstract Number: 1427
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
11:30AM-11:45AM
Abstract Number: 1428
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
11:45AM-12:00PM
Abstract Number: 1429
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
2:00PM-2:15PM
Abstract Number: 1438
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
2:00PM-2:15PM
Abstract Number: 1442
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
2:00PM-2:15PM
Abstract Number: 1446
Trauma Is Associated with Flares in Systemic Lupus Erythematosus (SLE)
2:15PM-2:30PM
Abstract Number: 1439
Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
2:15PM-2:30PM
Abstract Number: 1447
Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
2:15PM-2:30PM
Abstract Number: 1443
Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
2:30PM-2:45PM
Abstract Number: 1444
Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
2:30PM-2:45PM
Abstract Number: 1440
Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
2:30PM-2:45PM
Abstract Number: 1448
Virtual Visits versus Face-to-Face Visits for Rheumatoid Arthritis (RA): Comparison of Treat to Target (TTT) Adherence in 18 US Rheumatology Practices
2:45PM-3:00PM
Abstract Number: 1445
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
2:45PM-3:00PM
Abstract Number: 1449
Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
2:45PM-3:00PM
Abstract Number: 1441
Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases
3:00PM-3:15PM
Abstract Number: 1450
Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-based Cohort of Patients with Rheumatoid Arthritis
3:15PM-3:30PM
Abstract Number: 1451
Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
3:30PM-3:45PM
Abstract Number: 1452
COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study
3:30PM-3:45PM
Abstract Number: 1458
Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study
3:45PM-4:00PM
Abstract Number: 1459
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
3:45PM-4:00PM
Abstract Number: 1453
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
4:00PM-4:15PM
Abstract Number: 1464
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
4:00PM-4:15PM
Abstract Number: 1460
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
4:00PM-4:15PM
Abstract Number: 1454
RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis
4:15PM-4:30PM
Abstract Number: 1461
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
4:15PM-4:30PM
Abstract Number: 1455
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
4:15PM-4:30PM
Abstract Number: 1465
Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States
4:30PM-4:45PM
Abstract Number: 1456
Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
4:30PM-4:45PM
Abstract Number: 1462
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
4:30PM-4:45PM
Abstract Number: 1466
Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
4:45PM-5:00PM
Abstract Number: 1457
Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
4:45PM-5:00PM
Abstract Number: 1467
Determinants of Cervical Cancer Screening Patterns Among Women with Systemic Lupus Erythematosus
4:45PM-5:00PM
Abstract Number: 1463
Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 1610
“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
8:30AM-10:30AM
Abstract Number: 1864
18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis
8:30AM-10:30AM
Abstract Number: 1707
A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1639
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
8:30AM-10:30AM
Abstract Number: 1779
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
8:30AM-10:30AM
Abstract Number: 1781
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
8:30AM-10:30AM
Abstract Number: 1496
A Metagenome-wide Association Study Revealed Disease-specific Landscape of the Gut Microbiome of Systemic Lupus Erythematosus in Japanese
8:30AM-10:30AM
Abstract Number: 1560
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
8:30AM-10:30AM
Abstract Number: 1486
A Novel Requirement for IFNβ1 Signaling for IFNκ Induction in Keratinocytes
8:30AM-10:30AM
Abstract Number: 1492
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
8:30AM-10:30AM
Abstract Number: 1611
A Population-Based Evaluation of Telemedicine Use and Satisfaction in SLE Patients During the COVID-19 Pandemic in Atlanta, Georgia
8:30AM-10:30AM
Abstract Number: 1726
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
8:30AM-10:30AM
Abstract Number: 1876
A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome
8:30AM-10:30AM
Abstract Number: 1721
A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1683
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
8:30AM-10:30AM
Abstract Number: 1646
Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging
8:30AM-10:30AM
Abstract Number: 1616
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
8:30AM-10:30AM
Abstract Number: 1536
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 1592
ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1768
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity
8:30AM-10:30AM
Abstract Number: 1538
Adverse Events After SARS-CoV-2 Vaccination Among Rheumatology Outpatients in New York City
8:30AM-10:30AM
Abstract Number: 1712
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
8:30AM-10:30AM
Abstract Number: 1514
Age-related Metabolic Reprogramming of Memory CD4+ T Cells Is Associated with Reactive Oxygen Species-induced Immune Cell Dysfunction
8:30AM-10:30AM
Abstract Number: 1800
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
8:30AM-10:30AM
Abstract Number: 1759
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 1478
An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy
8:30AM-10:30AM
Abstract Number: 1741
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
8:30AM-10:30AM
Abstract Number: 1540
Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
8:30AM-10:30AM
Abstract Number: 1703
AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1794
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Psoriatic Arthritis Patients
8:30AM-10:30AM
Abstract Number: 1570
AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study
8:30AM-10:30AM
Abstract Number: 1568
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
8:30AM-10:30AM
Abstract Number: 1797
Are Smoking and Alcohol Associated with Peripheral Musculoskeletal Involvement in Patients with Spondyloarthritis? Results from the ASAS-PerSpA Study
8:30AM-10:30AM
Abstract Number: 1597
Arthritis Patient Perspectives on Virtual Care for People Living with Arthritis During the COVID-19 Pandemic and for the Future
8:30AM-10:30AM
Abstract Number: 1504
Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE
8:30AM-10:30AM
Abstract Number: 1666
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
8:30AM-10:30AM
Abstract Number: 1777
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 1786
Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab
8:30AM-10:30AM
Abstract Number: 1493
Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort
8:30AM-10:30AM
Abstract Number: 1681
ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450 + MTX vs PBO + MTX in MTX IR Patients
8:30AM-10:30AM
Abstract Number: 1521
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
8:30AM-10:30AM
Abstract Number: 1772
Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
8:30AM-10:30AM
Abstract Number: 1474
Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study
8:30AM-10:30AM
Abstract Number: 1484
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1562
B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
8:30AM-10:30AM
Abstract Number: 1746
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
8:30AM-10:30AM
Abstract Number: 1763
Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus 
8:30AM-10:30AM
Abstract Number: 1642
Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
8:30AM-10:30AM
Abstract Number: 1727
Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes
8:30AM-10:30AM
Abstract Number: 1747
BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
8:30AM-10:30AM
Abstract Number: 1885
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
8:30AM-10:30AM
Abstract Number: 1774
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
8:30AM-10:30AM
Abstract Number: 1769
BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
8:30AM-10:30AM
Abstract Number: 1859
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
8:30AM-10:30AM
Abstract Number: 1617
Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 1840
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
8:30AM-10:30AM
Abstract Number: 1470
Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples
8:30AM-10:30AM
Abstract Number: 1565
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
8:30AM-10:30AM
Abstract Number: 1479
CD14, a Toll-like Receptor Co-Factor, Influences Osteoclast Differentiation and Activity, but Does Not Alter Osteoblastic Potential of Bone-Marrow Precursors in Mice
8:30AM-10:30AM
Abstract Number: 1720
Cervical Dysplasia and HPV Infection in Women with Vasculitis
8:30AM-10:30AM
Abstract Number: 1596
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
8:30AM-10:30AM
Abstract Number: 1664
Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study
8:30AM-10:30AM
Abstract Number: 1473
Chaperone-mediated Autophagy Is a Hallmark of Joint Damage in Osteoarthritic Patients
8:30AM-10:30AM
Abstract Number: 1472
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1871
Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data
8:30AM-10:30AM
Abstract Number: 1784
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
8:30AM-10:30AM
Abstract Number: 1477
Circulating MicroRNAs in Hand Osteoarthritis
8:30AM-10:30AM
Abstract Number: 1756
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
8:30AM-10:30AM
Abstract Number: 1733
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
8:30AM-10:30AM
Abstract Number: 1813
Clinical Characteristics & Outcomes Associate with Work Productivity in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
8:30AM-10:30AM
Abstract Number: 1563
Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study
8:30AM-10:30AM
Abstract Number: 1882
Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
8:30AM-10:30AM
Abstract Number: 1625
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
8:30AM-10:30AM
Abstract Number: 1528
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
8:30AM-10:30AM
Abstract Number: 1544
Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
8:30AM-10:30AM
Abstract Number: 1632
Clinical Features and Colchicine Response in Patients with Undifferentiated Systemic Autoinflammatory Disease Carrying E148Q vs. Other MEFV Mutations
8:30AM-10:30AM
Abstract Number: 1638
Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 1555
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
8:30AM-10:30AM
Abstract Number: 1710
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
8:30AM-10:30AM
Abstract Number: 1697
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
8:30AM-10:30AM
Abstract Number: 1696
Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
8:30AM-10:30AM
Abstract Number: 1516
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
8:30AM-10:30AM
Abstract Number: 1757
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
8:30AM-10:30AM
Abstract Number: 1862
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
8:30AM-10:30AM
Abstract Number: 1654
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
8:30AM-10:30AM
Abstract Number: 1870
Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
8:30AM-10:30AM
Abstract Number: 1773
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
8:30AM-10:30AM
Abstract Number: 1802
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
8:30AM-10:30AM
Abstract Number: 1761
Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase
8:30AM-10:30AM
Abstract Number: 1817
Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
8:30AM-10:30AM
Abstract Number: 1533
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
8:30AM-10:30AM
Abstract Number: 1574
Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
8:30AM-10:30AM
Abstract Number: 1657
Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1595
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 1519
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
8:30AM-10:30AM
Abstract Number: 1863
Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study
8:30AM-10:30AM
Abstract Number: 1731
Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1850
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON
8:30AM-10:30AM
Abstract Number: 1513
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
8:30AM-10:30AM
Abstract Number: 1812
Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program
8:30AM-10:30AM
Abstract Number: 1671
COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
8:30AM-10:30AM
Abstract Number: 1637
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
8:30AM-10:30AM
Abstract Number: 1594
COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 1603
COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center
8:30AM-10:30AM
Abstract Number: 1524
COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
8:30AM-10:30AM
Abstract Number: 1554
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
8:30AM-10:30AM
Abstract Number: 1589
COVID-19 Vaccine Hesitancy in Rheumatology Patients
8:30AM-10:30AM
Abstract Number: 1583
Creation of an Ultrasonographic Scoring System for CPPD Extent: Results from a Delphi Process by the OMERACT US Working Group – CPPD Subgroup
8:30AM-10:30AM
Abstract Number: 1810
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
8:30AM-10:30AM
Abstract Number: 1767
CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
8:30AM-10:30AM
Abstract Number: 1508
Decrease of Angiogenic T Cells Associated to the Presence of Interstitial Lung Disease in Patients with Connective Tissue Diseases
8:30AM-10:30AM
Abstract Number: 1879
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
8:30AM-10:30AM
Abstract Number: 1880
Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
8:30AM-10:30AM
Abstract Number: 1806
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
8:30AM-10:30AM
Abstract Number: 1576
Development of a Plain Radiographic Scoring System for New Bone Formation in Gout
8:30AM-10:30AM
Abstract Number: 1526
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
8:30AM-10:30AM
Abstract Number: 1582
Diagnostic Accuracy and Reliability of Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease by Using New Definitions: An Ancillary Study of the OMERACT Ultrasound – CPPD Group
8:30AM-10:30AM
Abstract Number: 1872
Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy
8:30AM-10:30AM
Abstract Number: 1830
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
8:30AM-10:30AM
Abstract Number: 1730
Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
8:30AM-10:30AM
Abstract Number: 1782
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
8:30AM-10:30AM
Abstract Number: 1854
Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
8:30AM-10:30AM
Abstract Number: 1618
Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib
8:30AM-10:30AM
Abstract Number: 1587
Do Physical Therapists Use Recommended Treatments for Chronic Low Back Pain?
8:30AM-10:30AM
Abstract Number: 1520
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
8:30AM-10:30AM
Abstract Number: 1542
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
8:30AM-10:30AM
Abstract Number: 1483
Down-regulation of Hematopoietic Progenitor Kinase 1 by Aberrant Epigenetic Alterations in T Follicular Helper Cells Accounts for Excessive Immunity in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1796
Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study
8:30AM-10:30AM
Abstract Number: 1851
Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1734
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
8:30AM-10:30AM
Abstract Number: 1754
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1629
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
8:30AM-10:30AM
Abstract Number: 1569
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
8:30AM-10:30AM
Abstract Number: 1846
Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
8:30AM-10:30AM
Abstract Number: 1527
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
8:30AM-10:30AM
Abstract Number: 1529
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
8:30AM-10:30AM
Abstract Number: 1679
Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
8:30AM-10:30AM
Abstract Number: 1674
Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
8:30AM-10:30AM
Abstract Number: 1732
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
8:30AM-10:30AM
Abstract Number: 1677
Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1702
Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1844
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
8:30AM-10:30AM
Abstract Number: 1685
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study
8:30AM-10:30AM
Abstract Number: 1686
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy
8:30AM-10:30AM
Abstract Number: 1740
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
8:30AM-10:30AM
Abstract Number: 1742
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
8:30AM-10:30AM
Abstract Number: 1820
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
8:30AM-10:30AM
Abstract Number: 1811
Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
8:30AM-10:30AM
Abstract Number: 1667
Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
8:30AM-10:30AM
Abstract Number: 1809
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1823
Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies
8:30AM-10:30AM
Abstract Number: 1752
Efficacy of Voclosporin in Recent Onset Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1571
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
8:30AM-10:30AM
Abstract Number: 1645
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1518
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
8:30AM-10:30AM
Abstract Number: 1543
Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study
8:30AM-10:30AM
Abstract Number: 1633
Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review
8:30AM-10:30AM
Abstract Number: 1861
Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin
8:30AM-10:30AM
Abstract Number: 1512
Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy
8:30AM-10:30AM
Abstract Number: 1695
Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment
8:30AM-10:30AM
Abstract Number: 1764
Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
8:30AM-10:30AM
Abstract Number: 1701
Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up
8:30AM-10:30AM
Abstract Number: 1530
Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
8:30AM-10:30AM
Abstract Number: 1887
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
8:30AM-10:30AM
Abstract Number: 1549
Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
8:30AM-10:30AM
Abstract Number: 1714
Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1500
Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1612
Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 1602
Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
8:30AM-10:30AM
Abstract Number: 1723
Factors Associated with Postpartum Flare in Women with Lupus
8:30AM-10:30AM
Abstract Number: 1849
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
8:30AM-10:30AM
Abstract Number: 1678
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
8:30AM-10:30AM
Abstract Number: 1771
First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
8:30AM-10:30AM
Abstract Number: 1550
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1494
Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
8:30AM-10:30AM
Abstract Number: 1838
Further Construct Validation of the
8:30AM-10:30AM
Abstract Number: 1799
Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1551
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
8:30AM-10:30AM
Abstract Number: 1581
Genetic Effects on the Transition from Hyperuricemia to Gout
8:30AM-10:30AM
Abstract Number: 1735
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
8:30AM-10:30AM
Abstract Number: 1485
Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1808
Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
8:30AM-10:30AM
Abstract Number: 1600
Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?
8:30AM-10:30AM
Abstract Number: 1605
Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic
8:30AM-10:30AM
Abstract Number: 1852
Healthcare Utilization and Economic Burden in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1539
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
8:30AM-10:30AM
Abstract Number: 1725
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
8:30AM-10:30AM
Abstract Number: 1839
Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
8:30AM-10:30AM
Abstract Number: 1762
Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications
8:30AM-10:30AM
Abstract Number: 1753
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
8:30AM-10:30AM
Abstract Number: 1875
Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole
8:30AM-10:30AM
Abstract Number: 1566
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
8:30AM-10:30AM
Abstract Number: 1489
Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
8:30AM-10:30AM
Abstract Number: 1650
Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
8:30AM-10:30AM
Abstract Number: 1499
Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice
8:30AM-10:30AM
Abstract Number: 1546
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
8:30AM-10:30AM
Abstract Number: 1557
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1537
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
8:30AM-10:30AM
Abstract Number: 1793
Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
8:30AM-10:30AM
Abstract Number: 1680
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
8:30AM-10:30AM
Abstract Number: 1591
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
8:30AM-10:30AM
Abstract Number: 1623
Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
8:30AM-10:30AM
Abstract Number: 1599
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
8:30AM-10:30AM
Abstract Number: 1682
Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 1744
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
8:30AM-10:30AM
Abstract Number: 1788
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 1684
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
8:30AM-10:30AM
Abstract Number: 1865
Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
8:30AM-10:30AM
Abstract Number: 1659
Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
8:30AM-10:30AM
Abstract Number: 1643
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1670
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
8:30AM-10:30AM
Abstract Number: 1755
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
8:30AM-10:30AM
Abstract Number: 1711
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
8:30AM-10:30AM
Abstract Number: 1648
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1586
Individuals with Pre-arthritic Hip Pain Walk with Hip Motion Alteration Common in Individuals with Hip OA
8:30AM-10:30AM
Abstract Number: 1505
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 1687
Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
8:30AM-10:30AM
Abstract Number: 1698
Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years
8:30AM-10:30AM
Abstract Number: 1647
Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA
8:30AM-10:30AM
Abstract Number: 1770
Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
8:30AM-10:30AM
Abstract Number: 1577
Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
8:30AM-10:30AM
Abstract Number: 1468
Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model
8:30AM-10:30AM
Abstract Number: 1867
Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis
8:30AM-10:30AM
Abstract Number: 1511
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
8:30AM-10:30AM
Abstract Number: 1775
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1766
Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
8:30AM-10:30AM
Abstract Number: 1750
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
8:30AM-10:30AM
Abstract Number: 1510
Joint CD8+ Tissue Resident Memory Cell Activation Produces Local Inflammatory Arthritis
8:30AM-10:30AM
Abstract Number: 1497
Kidney Disease in Lupus Patients Is Linked to Monocytes’ Aberrant Spliceosome and Altered Expression of IFN-Response Related Genes
8:30AM-10:30AM
Abstract Number: 1837
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
8:30AM-10:30AM
Abstract Number: 1482
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
8:30AM-10:30AM
Abstract Number: 1480
LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis
8:30AM-10:30AM
Abstract Number: 1475
Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants
8:30AM-10:30AM
Abstract Number: 1627
Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
8:30AM-10:30AM
Abstract Number: 1641
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review
8:30AM-10:30AM
Abstract Number: 1692
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: 3-year Results from the SELECT-EARLY Study
8:30AM-10:30AM
Abstract Number: 1760
Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1709
Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
8:30AM-10:30AM
Abstract Number: 1803
Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
8:30AM-10:30AM
Abstract Number: 1691
Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
8:30AM-10:30AM
Abstract Number: 1502
Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
8:30AM-10:30AM
Abstract Number: 1469
Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries
8:30AM-10:30AM
Abstract Number: 1535
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
8:30AM-10:30AM
Abstract Number: 1805
Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1553
Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
8:30AM-10:30AM
Abstract Number: 1693
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
8:30AM-10:30AM
Abstract Number: 1481
Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement
8:30AM-10:30AM
Abstract Number: 1672
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
8:30AM-10:30AM
Abstract Number: 1488
Metabolic Alterations of Systemic Lupus Erythematosus NK Cells Determine Response to Anti-CD38 and Anti-SLAMF7 Monoclonal Antibodies
8:30AM-10:30AM
Abstract Number: 1476
Metabolic Reprogramming: Inhibiting Osteoarthritis-induced Expression of the Pyruvate Dehydrogenase Kinase Preserves Mitochondrial Respiration
8:30AM-10:30AM
Abstract Number: 1532
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
8:30AM-10:30AM
Abstract Number: 1622
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
8:30AM-10:30AM
Abstract Number: 1669
Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography
8:30AM-10:30AM
Abstract Number: 1501
Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS
8:30AM-10:30AM
Abstract Number: 1724
More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database
8:30AM-10:30AM
Abstract Number: 1556
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
8:30AM-10:30AM
Abstract Number: 1495
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
8:30AM-10:30AM
Abstract Number: 1640
Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions
8:30AM-10:30AM
Abstract Number: 1630
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
8:30AM-10:30AM
Abstract Number: 1490
Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity
8:30AM-10:30AM
Abstract Number: 1564
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
8:30AM-10:30AM
Abstract Number: 1635
Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?
8:30AM-10:30AM
Abstract Number: 1783
National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017
8:30AM-10:30AM
Abstract Number: 1883
Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
8:30AM-10:30AM
Abstract Number: 1868
Neutrophil Extracellular Trap Formation in Patients with Vasculitis
8:30AM-10:30AM
Abstract Number: 1531
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
8:30AM-10:30AM
Abstract Number: 1578
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
8:30AM-10:30AM
Abstract Number: 1717
One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
8:30AM-10:30AM
Abstract Number: 1471
Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice
8:30AM-10:30AM
Abstract Number: 1523
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
8:30AM-10:30AM
Abstract Number: 1836
Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1613
Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1719
Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1649
Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder
8:30AM-10:30AM
Abstract Number: 1792
Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands
8:30AM-10:30AM
Abstract Number: 1634
Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives
8:30AM-10:30AM
Abstract Number: 1814
Patient Characteristics and Clinical Features Associate with Health-Related Quality of Life in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
8:30AM-10:30AM
Abstract Number: 1624
Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
8:30AM-10:30AM
Abstract Number: 1620
Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry
8:30AM-10:30AM
Abstract Number: 1636
Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents
8:30AM-10:30AM
Abstract Number: 1593
Perceived Impact of the COVID-19 Pandemic on Physical Activity Among Adult Patients with Rheumatologic Disease
8:30AM-10:30AM
Abstract Number: 1604
Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry
8:30AM-10:30AM
Abstract Number: 1843
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
8:30AM-10:30AM
Abstract Number: 1842
Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
8:30AM-10:30AM
Abstract Number: 1700
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
8:30AM-10:30AM
Abstract Number: 1567
Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
8:30AM-10:30AM
Abstract Number: 1509
Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
8:30AM-10:30AM
Abstract Number: 1829
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
8:30AM-10:30AM
Abstract Number: 1579
Phenome-Wide Association of Gout Risk Loci
8:30AM-10:30AM
Abstract Number: 1665
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1498
Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 1653
Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1547
Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome
8:30AM-10:30AM
Abstract Number: 1522
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
8:30AM-10:30AM
Abstract Number: 1559
Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India
8:30AM-10:30AM
Abstract Number: 1745
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
8:30AM-10:30AM
Abstract Number: 1729
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
8:30AM-10:30AM
Abstract Number: 1789
Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
8:30AM-10:30AM
Abstract Number: 1631
Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
8:30AM-10:30AM
Abstract Number: 1831
Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry
8:30AM-10:30AM
Abstract Number: 1541
Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
8:30AM-10:30AM
Abstract Number: 1614
Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
8:30AM-10:30AM
Abstract Number: 1841
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
8:30AM-10:30AM
Abstract Number: 1785
Prevalence and Incidence of PsA in Germany – a Cohort Study with 65 Million Participants
8:30AM-10:30AM
Abstract Number: 1517
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
8:30AM-10:30AM
Abstract Number: 1561
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
8:30AM-10:30AM
Abstract Number: 1515
Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
8:30AM-10:30AM
Abstract Number: 1715
Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians
8:30AM-10:30AM
Abstract Number: 1791
Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry
8:30AM-10:30AM
Abstract Number: 1827
Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
8:30AM-10:30AM
Abstract Number: 1503
Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging
8:30AM-10:30AM
Abstract Number: 1548
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
8:30AM-10:30AM
Abstract Number: 1780
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1815
Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
8:30AM-10:30AM
Abstract Number: 1884
Real-life Data for the Use of Anti-TNF Treatment in DADA2
8:30AM-10:30AM
Abstract Number: 1818
Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
8:30AM-10:30AM
Abstract Number: 1826
Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1737
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
8:30AM-10:30AM
Abstract Number: 1790
Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
8:30AM-10:30AM
Abstract Number: 1584
Relation of Depressive Symptoms to Alterations in Conditioned Pain Modulation in Knee Osteoarthritis: The Multicenter Osteoarthritis Study (MOST)
8:30AM-10:30AM
Abstract Number: 1588
Relation of Foot and Ankle Pain to Worsening Knee Pain: The MOST Study
8:30AM-10:30AM
Abstract Number: 1660
Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
8:30AM-10:30AM
Abstract Number: 1822
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
8:30AM-10:30AM
Abstract Number: 1807
Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
8:30AM-10:30AM
Abstract Number: 1628
Reproductive Health Knowledge Gaps, Needs, and Barriers Identified by Pediatric Rheumatology Providers
8:30AM-10:30AM
Abstract Number: 1615
Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis
8:30AM-10:30AM
Abstract Number: 1673
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
8:30AM-10:30AM
Abstract Number: 1525
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
8:30AM-10:30AM
Abstract Number: 1833
Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
8:30AM-10:30AM
Abstract Number: 1675
Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
8:30AM-10:30AM
Abstract Number: 1658
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1722
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
8:30AM-10:30AM
Abstract Number: 1713
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
8:30AM-10:30AM
Abstract Number: 1507
Role of CD4+ T Cells in the Pathogenesis of RA: Immunization with Citrullinated T Cell Epitopes Is Sufficient to Induce Immunological and Clinical Manifestations of Arthritis in DR4-Transgenic Mice
8:30AM-10:30AM
Abstract Number: 1821
Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies
8:30AM-10:30AM
Abstract Number: 1690
Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
8:30AM-10:30AM
Abstract Number: 1676
Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice
8:30AM-10:30AM
Abstract Number: 1545
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
8:30AM-10:30AM
Abstract Number: 1688
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis
8:30AM-10:30AM
Abstract Number: 1828
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
8:30AM-10:30AM
Abstract Number: 1689
Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
8:30AM-10:30AM
Abstract Number: 1609
SARS-CoV-2 Vaccination Willingness and Its Predictors in Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)
8:30AM-10:30AM
Abstract Number: 1601
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
8:30AM-10:30AM
Abstract Number: 1853
Scleroderma Presentation in the Canadian Scleroderma Research Group Indigenous Population
8:30AM-10:30AM
Abstract Number: 1835
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
8:30AM-10:30AM
Abstract Number: 1825
Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
8:30AM-10:30AM
Abstract Number: 1832
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
8:30AM-10:30AM
Abstract Number: 1824
Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study
8:30AM-10:30AM
Abstract Number: 1621
Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?
8:30AM-10:30AM
Abstract Number: 1856
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
8:30AM-10:30AM
Abstract Number: 1858
Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
8:30AM-10:30AM
Abstract Number: 1655
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
8:30AM-10:30AM
Abstract Number: 1534
Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
8:30AM-10:30AM
Abstract Number: 1847
Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1661
Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)
8:30AM-10:30AM
Abstract Number: 1765
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?
8:30AM-10:30AM
Abstract Number: 1491
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
8:30AM-10:30AM
Abstract Number: 1845
Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1506
SLAMF6 Compartmentalization Regulates Autoimmune T Cell Responses
8:30AM-10:30AM
Abstract Number: 1739
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
8:30AM-10:30AM
Abstract Number: 1590
Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases
8:30AM-10:30AM
Abstract Number: 1608
Sources of Information About SARS-CoV-2 Used by Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)
8:30AM-10:30AM
Abstract Number: 1776
Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial
8:30AM-10:30AM
Abstract Number: 1644
Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study
8:30AM-10:30AM
Abstract Number: 1585
Suprascapular Nerve Block for the Treatment of Adhesive Capsulitis
8:30AM-10:30AM
Abstract Number: 1881
Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease
8:30AM-10:30AM
Abstract Number: 1694
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
8:30AM-10:30AM
Abstract Number: 1652
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1651
Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis
8:30AM-10:30AM
Abstract Number: 1552
Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection
8:30AM-10:30AM
Abstract Number: 1877
Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
8:30AM-10:30AM
Abstract Number: 1728
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
8:30AM-10:30AM
Abstract Number: 1804
Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
8:30AM-10:30AM
Abstract Number: 1606
Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences
8:30AM-10:30AM
Abstract Number: 1716
Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center
8:30AM-10:30AM
Abstract Number: 1699
The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome
8:30AM-10:30AM
Abstract Number: 1801
The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1708
The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study
8:30AM-10:30AM
Abstract Number: 1705
The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users
8:30AM-10:30AM
Abstract Number: 1607
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
8:30AM-10:30AM
Abstract Number: 1873
The Importance of Lower Extremity Vein Wall Thickness in Patients with Behcet’s Syndrome
8:30AM-10:30AM
Abstract Number: 1663
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
8:30AM-10:30AM
Abstract Number: 1748
The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)
8:30AM-10:30AM
Abstract Number: 1778
The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis
8:30AM-10:30AM
Abstract Number: 1869
The Role of Faecal Calprotectin in IgA Vasculitis
8:30AM-10:30AM
Abstract Number: 1798
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
8:30AM-10:30AM
Abstract Number: 1558
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
8:30AM-10:30AM
Abstract Number: 1860
Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients
8:30AM-10:30AM
Abstract Number: 1819
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
8:30AM-10:30AM
Abstract Number: 1834
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
8:30AM-10:30AM
Abstract Number: 1878
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
8:30AM-10:30AM
Abstract Number: 1704
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
8:30AM-10:30AM
Abstract Number: 1736
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
8:30AM-10:30AM
Abstract Number: 1816
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
8:30AM-10:30AM
Abstract Number: 1749
Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period
8:30AM-10:30AM
Abstract Number: 1598
Trends in Medication Interruptions and Associations with Disease Flares During a Public Health Crisis: Longitudinal Data from Patients with Autoimmune Rheumatic Diseases During the COVID-19 Pandemic
8:30AM-10:30AM
Abstract Number: 1706
Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis
8:30AM-10:30AM
Abstract Number: 1487
Type I Interferon Modulates Langerhans Cell ADAM17 in Lupus to Contribute to Photosensitivity
8:30AM-10:30AM
Abstract Number: 1857
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1572
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
8:30AM-10:30AM
Abstract Number: 1668
Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort
8:30AM-10:30AM
Abstract Number: 1662
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
8:30AM-10:30AM
Abstract Number: 1848
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1855
Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis
8:30AM-10:30AM
Abstract Number: 1575
Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response
8:30AM-10:30AM
Abstract Number: 1718
Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
8:30AM-10:30AM
Abstract Number: 1626
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
8:30AM-10:30AM
Abstract Number: 1888
Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
8:30AM-10:30AM
Abstract Number: 1874
Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
8:30AM-10:30AM
Abstract Number: 1738
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
8:30AM-10:30AM
Abstract Number: 1886
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
8:30AM-10:30AM
Abstract Number: 1795
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study
8:30AM-10:30AM
Abstract Number: 1573
Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors
8:30AM-10:30AM
Abstract Number: 1866
Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients
8:30AM-10:30AM
Abstract Number: 1751
Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
8:30AM-10:30AM
Abstract Number: 1787
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
8:30AM-10:30AM
Abstract Number: 1619
Where Do Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric COVID-19 Fit Under the Cytokine Storm Syndrome Umbrella?
8:30AM-10:30AM
Abstract Number: 1580
Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis
8:30AM-10:30AM
Abstract Number: 1743
Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
8:30AM-10:30AM
Abstract Number: 1758
WITHDRAWN
8:30AM-10:30AM
Abstract Number: 1656
Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study
9:00AM-9:15AM
Abstract Number: 1889
Arthritogenic T Cells Harbor a Transcriptional Program of T Cell Activation and a Repertoire Pruned by Endogenous Superantigen
9:15AM-9:30AM
Abstract Number: 1890
Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
9:30AM-9:45AM
Abstract Number: 1891
Variable Effects of Testosterone on Male versus Female Derived Macrophages in Inflammatory Arthritis
9:45AM-10:00AM
Abstract Number: 1892
Promotion of Autoimmune Arthritis via Tryptophan Metabolism and Production of the Bacterial-Derived Tryptophan Metabolite Indole
10:30AM-10:45AM
Abstract Number: 1893
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
10:30AM-10:45AM
Abstract Number: 1897
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
10:30AM-10:45AM
Abstract Number: L16
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
10:30AM-10:45AM
Abstract Number: 1901
Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project
10:45AM-11:00AM
Abstract Number: L17
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
10:45AM-11:00AM
Abstract Number: 1902
Gait Alterations Associated with Worsening Knee Pain over 2 Years: A Machine-learning Approach in the MultiCenter Osteoarthritis Study
10:45AM-11:00AM
Abstract Number: 1894
Natural Language Processing Tool for Extraction of Patient-Reported Outcomes from a National Multi-Electronic Health Records Registry
10:45AM-11:00AM
Abstract Number: 1898
Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis
11:00AM-11:15AM
Abstract Number: 1895
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
11:00AM-11:15AM
Abstract Number: 1903
Does Limited Stair Climbing Lead to Poor Future Health? The Relationship Between Short-term Trajectories of Stair Climbing Frequency and Incident Slow Gait Speed over 1 and 2 Years in Adults with Knee Osteoarthritis
11:00AM-11:15AM
Abstract Number: L18
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
11:00AM-11:15AM
Abstract Number: 1899
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
11:15AM-11:30AM
Abstract Number: 1904
“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
11:15AM-11:30AM
Abstract Number: 1896
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
11:15AM-11:30AM
Abstract Number: L19
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
11:15AM-11:30AM
Abstract Number: 1900
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
11:30AM-11:45AM
Abstract Number: L20
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
11:45AM-12:00PM
Abstract Number: L21
Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial
2:00PM-2:15PM
Abstract Number: 1905
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
2:00PM-2:15PM
Abstract Number: 1919
Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis
2:00PM-2:15PM
Abstract Number: 1909
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
2:00PM-2:15PM
Abstract Number: 1915
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
2:15PM-2:30PM
Abstract Number: 1916
Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
2:15PM-2:30PM
Abstract Number: 1910
Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
2:15PM-2:30PM
Abstract Number: 1920
Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
2:15PM-2:30PM
Abstract Number: 1906
IL-13Ra1-Mediated Signaling Regulates Age-Associated/Autoimmune B-Cell Expansion and Lupus Pathogenesis
2:30PM-2:45PM
Abstract Number: 1921
Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings
2:30PM-2:45PM
Abstract Number: 1907
Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study
2:30PM-2:45PM
Abstract Number: 1911
Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study
2:30PM-2:45PM
Abstract Number: 1917
Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels
2:45PM-3:00PM
Abstract Number: 1918
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
2:45PM-3:00PM
Abstract Number: 1922
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
2:45PM-3:00PM
Abstract Number: 1908
Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
2:45PM-3:00PM
Abstract Number: 1912
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
3:00PM-3:15PM
Abstract Number: 1913
Patient Perceptions of Telemedicine Use in Rheumatology Clinics During the COVID-19 Pandemic: An Analysis from the COVID-19 Global Rheumatology Alliance
3:15PM-3:30PM
Abstract Number: 1914
Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
3:30PM-3:45PM
Abstract Number: 1923
Has the Incidence of Total Joint Arthroplasty in Rheumatoid Arthritis Decreased in the Era of Biologics Use? A Population-based Incident Cohort Study 1995–2015
3:30PM-3:45PM
Abstract Number: 1927
Heterogeneity of Juvenile Idiopathic Arthritis Synovial Fibroblasts Correlates to Disease Progression and Provides Compelling Diagnostic Data
3:30PM-3:45PM
Abstract Number: 1931
The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
3:45PM-4:00PM
Abstract Number: 1932
Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
3:45PM-4:00PM
Abstract Number: 1928
In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

3:45PM-4:00PM
Abstract Number: 1924
Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets
4:00PM-4:15PM
Abstract Number: 1933
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
4:00PM-4:15PM
Abstract Number: 1929
Metabolomics Identifies Early Mechanisms of Atherogenic Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation
4:00PM-4:15PM
Abstract Number: 1943
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
4:00PM-4:15PM
Abstract Number: 1939
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
4:00PM-4:15PM
Abstract Number: 1925
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
4:00PM-4:15PM
Abstract Number: 1935
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
4:15PM-4:30PM
Abstract Number: 1936
A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
4:15PM-4:30PM
Abstract Number: 1926
Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
4:15PM-4:30PM
Abstract Number: 1934
Intra-Individual Change in Cognitive Function Among Adults with Systemic Lupus Erythematosus: A Markov Analysis over 7 Years
4:15PM-4:30PM
Abstract Number: 1940
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
4:15PM-4:30PM
Abstract Number: 1930
Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease
4:15PM-4:30PM
Abstract Number: 1944
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
4:30PM-4:45PM
Abstract Number: 1945
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
4:30PM-4:45PM
Abstract Number: 1937
IL-16 Is Linked to Lupus Nephritis Activity
4:30PM-4:45PM
Abstract Number: 1941
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
4:45PM-5:00PM
Abstract Number: 1938
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
4:45PM-5:00PM
Abstract Number: 1942
Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies
4:45PM-5:00PM
Abstract Number: 1946
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial

« View all sessions from this meeting